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ABSTRACT 
Cervical cancer is considered a common yet preventable cause of death 
in women. It has been estimated that about 420 women out of the 1400 
women diagnosed with cervical cancer will die during 5 years from diagnosis 
(National Cancer Institute of Canada, 2003). This study addresses the role of a 
member of the Rel!NF-KB family of genes, Xre/3, in the growth of the 
malignant HeLa cervical cells and its effect on chemotherapeutic treatment. 
The hypothesis of this study is that Rel!NF-KB promotes 
chemotherapeutic resistance in cancer cells. In order to study this problem, the 
amphibianXre/3, a Rel!NF-KB homologue, was used because it was 
previously shown to be constitutively active when transfected into HeLa cells, 
which normally do not express Rel!NF-KB. This allowed the opportunity to 
test whether Xrel3 expression imbues chemoresistant properties to these cells. 
The expression of Xrel3 slowed the growth of HeLa cervical cells 
associated with an increase in expression of the cell cycle inhibitor p21. The 
expression level of the apoptosis pathway protein caspase-8, its activated 
product and cleaved poly (ADP-ribose) polymerase, P ARP, were also 
VI 
elevated 6-fold relative to the non-induced state, perhaps associated with the 
initiation of apoptosis consequent to cell growth arrest. 
To determine the effect of chemotherapeutic agents on HeLa cells 
expressing Xrel3, cells were treated with the DNA-crosslinking and chelating 
agent, cisplatin. At 1 J.LM cisplatin, the expression of Xre/3 initiated an anti-
apoptotic effect after 24 hours of treatment, based on the expression of 
significantly lower levels of the apoptotic proteins, Bax (P<0.05), caspase-8 
(P<0.05) and MDM-2 (P<O.Ol). Furthermore, the level of the tumor 
suppressor protein p53 was suppressed by 3-fold, along with a reduction of 
caspase-3 and p21. The expression of the anti-apoptotic BAG-1 isoforms 
(P<0.01) was also increased. The expression ofXre/3 sensitizes HeLa cells to 
1 J.LM cisplatin after a lag period of three days, however, as assessed by a 
decrease in numbers of viable cells. 
After 24 hours of 5 J.LM cisplatin treatment, there was a significant 
increase in the levels of the pro-apoptotic proteins relative to controls, 
including Bax (P<0.05), MDM-2 (P<0.05), the cell cycle inhibitor p21 
(P<O.Ol), cleaved PARP, caspase-8, and caspase-3. However, p53 was 
significantly decreased (P<0.05) while BCL-2 (P<0.01) and BCL- XL 
(P<0.01) levels were elevated significantly. The level ofthe anti-apoptotic 
VII 
protein BAG-I remained constant (P<O.O 1) in cisplatin-treated Xrel3-
expressing cells. Despite the increased expression ofBAG-1, the balance 
between pro- and anti-apoptotic factors shifted towards increased expression 
of pro-apoptotic proteins. The Human Papillomavirus (HPV) oncoprotein E6 
expression was not affected by the transfected Xre/3 gene. 
These results suggested thatXre/3, a homolog of c-Rel, causes an anti-
apoptotic effect (chemoresistance) when cells are initially exposed to low 
cisplatin concentrations (1 ~·This result supports the hypothesis of this 
study. However, with prolonged contact to 1 ~ cisplatin or upon 24 hours 
exposure to 5 ~ cisplatin, Xrel3 had a synergistic apoptotic effect when 
coupled with cisplatin, thus promoting chemosensitivity and cell death. These 
results support the previously proposed idea that Rel/NF -KB proteins 
modulate their activity depending on cellular stress. 
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CHAPTER 1 INTRODUCTION 
1.1 Oncogenesis 
1.1.1 Etiology of Cervical Cancer 
The process of oncogenesis or carcinogenesis fundamentally emerges 
from defects in the balance between the activity of proto-oncogenes, which 
promote cell proliferation, and tumor suppressor genes, which regulate the 
cell cycle. It is known that DNA damage and repair occurs normally in 
every living cell. When the rate of DNA damage exceeds that of repair, 
accumulation of DNA damage and defects might trigger the initiation of 
cancer (Furomoto and Irahara, 2002, Munoz et al., 2003, Garland, 2002). 
Uterine cervical cancer is a serious gynecologic malignancy in 
women. There are two main types of cervical cancer, squamous cell cancer 
and adenocarcinoma, based on the type of cells that become cancerous. 
Cervical cancer is initiated when the combined action of a group of 
carcinogens cause the normal, physiological events associated with cervical 
metaplastic transformation to go awry and cause the formation of pre-
malignant dysplasia (Josefson, 1999). Poor prognosis is usually associated 
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with positive pelvic lymph nodes, indicating that the tumor cells have 
become metastatic (Kim et al., 2003). 
Recent studies have demonstrated that estrogen, which is the female 
sex hormone, might have a contributory role in increasing vaginal 
epithelium proliferation and thus promoting the malignant transformation of 
the squamous and columnar cells at the junction of the cervical and vaginal 
epithelium (Park et al., 2003). Infection by the Human Papilloma Virus, 
HPV, is a necessary requirement for cervical cancer, but not all women 
infected by this virus develop cervical cancer (Castellsague et al., 2002). 
Some HPV infections, for instance are associated with benign proliferation 
or wart formation. 
1.1.2 Human Papilloma Virus (HPV) 
HPV s are small DNA viruses that are known to be the most common 
etiological agents in cervical cancer (Ghim et al., 2002). More than 100 
types ofHPVs have been discovered, isolated and studied (See Table 1) 
(Sisk and Robertson, 2002). HPVs are implicated in the mucosal and 
epithelial infections that may range from a benign lesion to a malignant 
carcinoma (Garland, 2002). HPV has also been reported to be associated 
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with anal and genital cancers (Heilmann and Kreienberg, 2002). Preliminary 
findings suggested their involvement in some head and neck cancers as well 
(Sisk and Robertson, 2002). 
The high risk HPV 16 and HPV 18 are associated with malignant 
transformation and carcinogenesis in 85% of the diagnosed cervical cancer 
cases (Garland, 2002). Recent studies have shown that 13 different types of 
HPV are associated with carcinogenesis (Munoz et al., 2003). The most 
widely known factors associated with HPV are the E6 and E7 oncoproteins, 
which interact with p53 and Rb tumor suppressors respectively (Furumoto 
and Irahara, 2002). The interaction ofE6 and E7 with these cellular proteins 
results in their suppression (Ghim et al., 2002), thus disrupting the normal 
physiological process of programmed cell death in response to DNA damage 
(See Figure 1.1) (Finzer et al., 2002). In the presence of carcinogens, 
therefore, the accumulation of DNA damage without apoptosis is presumed 
to lead to cancer. 
It should be made clear that viral infection by itself does not cause 
cancer. It is the interaction of the viral genome with host genes that disrupts 
the normal cell cycle and transforms the cell into a pre-malignant state. For 
instance, some viruses might interact with specific genes (like tumor 
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suppressor genes mentioned above) in the host cells, switching some 
systems on or off, thus leaving the cell free to divide in an uncontrolled way 
and raising the risk of cancer (Zur Hausen et al., 2003). 
Other cellular proteins may be affected by HPV infection as well. For 
instance, cervical cancer cell lines showed overexpression of the anti-
apoptotic protein BAG-1, which might contribute to its malignant 
proliferation (Yang et al., 1998). Therefore, understanding the molecular 
mechanisms leading to this disease will be of importance for generating 
means for its early detection and possible prevention and treatment. 
5 
HPVE7 
SV40 
1-
----tt-~ E2F 
Cell proliferation 
HPV E6 
t----=oN-pS3 
Figure 1.1: A schematic representation ofRB/p53 interactions to 
regulate cell cycle and apoptosis (Adapted from Benett et al., 1998). Cell 
cycle transition from G1-S phase is mediated by RB interactions with the 
E2F transcription factor family, which is considered an important regulator 
of the cell cycle. Growth factors lead to the phosphorylation ofRB in late G1 
phase by cdk/cyclin. This is followed by the release ofE2F, allowing 
transcriptional activation ofE2F target genes, which promotes S-phase entry 
and cell proliferation. HPV E7 and Simian Virus 40 (SV 40) promote the 
release ofE2F from RB, whereas HPV E6 and the dominant negative, DN-
p53 inhibit p53 activity leading to cell proliferation. 
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Species Cancer Predominant viral types 
Humans Skin carcinomas HPV-5 -8 
' 
Lower genital tract cancers HPV-16, -18,-31,-33 
Malignant progression of respiratory HPV-6 -11 
' 
papillomas 
Cattle Alimentary-tract carcinoma HPV-4 
Eye and skin carcinoma Not characterized 
Sheep Skin carcinoma Not characterized 
Cottontail rabbit Skin carcinoma Cotton rabbit 
papillomavirus (CRPV) 
Table 1: Naturally occurring cancers associated with papillomaviruses 
(Sisk and Robertson, 2002, Zur Hausen et al., 2003). 
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1.2 Apoptosis 
1.2.1 Introduction 
Apoptosis, or programmed cell death, is orchestrated by a highly 
organized group of signaling pathway proteins (for review see Miller and 
Marx, 1998; Fiers et al., 1999). Apoptosis can be triggered by a variety of 
events the cell may face. For example, exposure to X-rays, ultraviolet light 
and chemotherapeutic drugs are factors that can initiate the process of 
apoptosis (for review, see Miller and Marx, 1998). 
One mechanism to protect an organism from the consequences of 
accumulated DNA damage involves a class of protein-splitting enzymes 
called caspases, which are activated upon detection of DNA damage and 
eventually cause cell death (for review, see Thornberry and. Lazebnik, 
1998). The control of programmed or physiological cell death acts as a 
protective mechanism for the organism because accumulation of DNA 
damage without concomitant repair could lead to the development of cancer, 
while unregulated apoptosis can cause autoimmune diseases. 
The process of apoptosis is essential in stopping the uncontrolled 
proliferation of cells (for review, see Nicholson, 2000). Any defects in this 
dynamic process may eventually lead to the development of benign 
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proliferative lesions or even malignant tumors (for review, see Nicholson, 
2000). Apoptosis can be initiated via specific receptors that are members of 
the tumor necrosis factor (TNF) receptor superfamily (for review, see 
Ashkenazi and Dixit, 1998). Such "Death receptors" are activated via 
binding of specific ligands (for review, see Ashkenazi and Dixit, 1998) and 
once they are activated, they can initiate apoptosis. However, the role of 
these receptors is not restricted to the initiation of apoptosis, but also 
includes other functions that differ from apoptosis and sometimes counteract 
apoptosis such as the recruitment and subsequent ligand binding of growth 
factors such as the Nerve Growth Factor (NGF) (for review, see Ashkenazi 
and Dixit, 1998). 
Another apoptotic pathway involves the mitochondria. Under stress, 
these essential organelles can release cytochrome c into the cytoplasm of the 
cell (for review, see Green and Reed, 1998). This cytochrome c release is a 
possible activator for caspases by the recruitment ofprocaspase-9, which 
undergoes conformational changes that leads to the activation of 
downstream, effector caspases (for review, see Green and Reed, 1998). 
Apoptosis acts as a double-edged sword. Despite its importance in 
restricting cell proliferation and maintaining constant cell number, excessive 
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apoptosis is associated with stroke, Alzheimer's disease and other 
neurodegenerative disorders (for review, see Yuan and Yankner, 2000). 
Damaged neurons in these disorders commit suicide inappropriately. 
Alzheimer's disease, for instance, was found to be associated with a genetic 
component that involves mutations in the chromosomes (1, 14, 21) as well 
as the tau gene on chromosome 1 7 and results in unscheduled or unregulated 
death of brain cells (Rich et al., 2000). 
Understanding the details and the signaling pathways of this 
phenomenon might be helpful in manipulating and intervening in the process 
of apoptosis. Apoptosis is required to restrict cell proliferation and to 
maintain a constant cell number. Attempts to suppress apoptosis, however, 
may be useful to treat neurodegenerative disorders, while attempts to 
activate apoptosis may be useful in disorders involving overproliferation. 
1.2.2 Regulators of apoptosis 
Many genes have been implicated in enhancing or inhibiting the 
process of apoptosis. They act by different mechanisms that ultimately 
contribute to either tumor suppression or progression, respectively. Four of 
the most important factors that regulate apoptosis are p53, the caspases, the 
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Bcl-2 family of proteins and PARP (Reed, 1997; Packham et al., 1997; for 
review, see Green, 2000). 
1.2.2.1 Caspases 
Caspases are the executioners of cell death. They receive the signals 
that enable them to initiate apoptosis. Cells undergoing apoptosis exhibit 
fragmentation of DNA, condensation of the chromatin, budding of the cell 
membrane and the formation of apoptotic bodies by dissociation of the cell 
and its constituents into membrane-enclosed vesicles (for review, see 
Thornberry and Lazebnik, 1998; Savill and Fadok, 2000). All caspases share 
a similar structure that consists of three domains: an NHrterminal peptide 
(prodomain), a large subunit (approximately 20 kD) and a small subunit 
(approximately 10 kD) (for review, see Hengartner, 2000). Caspases are 
expressed as procaspases, which undergo cleavage to the 2 subunits 
mentioned above (for review, see Meier et al., 2000). Cleavage of caspases 
is a sign of active apoptosis. The large and small subunits then associate to 
form a heterodimer (Boise et al., 1995; Reed, 1997). 
The exact mechanism of action of caspases is still unknown. 
However, several studies have shown that caspases exert both direct and 
indirect actions on the cell (for review, see Evan et al., 1998). The direct 
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action of caspases can be exemplified by their ability to act on cell structural 
integrity by destroying the nuclear lamina (Evan eta/., 1998) and cleaving 
the proteins responsible for regulating the cytoskeleton (Boyd eta/., 1995; 
Evan eta/., 1998). The indirect action of caspases is via their ability to 
inhibit the proteins that promote cell survival and growth (for review, see 
Hengartner, 2000). Among these proteins is the Bcl-2 family of proteins, 
which are cleaved by caspases resulting in inactivation of the Bcl-2 proteins 
and the release of a fragment that has a direct apoptotic effect (for review, 
see Evan eta/., 1998). 
Caspases-8, -9, and -1 0 are known to initiate the caspase activation 
cascade. However, caspases-3, -6 and -7 propagate the cascade and are 
activated by the proteolytic cleavage process mediated by other upstream 
caspases in the caspase cascade pathway (for review, see Hengartner, 2000). 
1.2.2.2 Bcl-2 family of proteins 
The Bcl-2 family of proteins has several members with various 
functions (for review, see Nicholson, 2000). The Bcl-2 gene family 
comprises pro-apoptotic and anti-apoptotic proteins sharing one or more 
Bcl-2 homology (BH) domains (Reed, 1997). The gene family is made up of 
3 main groups (for review, see Hengartner, 2000). Group I includes the anti-
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apoptotic members similar to Bcl-2. Group II includes the pro-apoptotic 
members like Bax and Bak, while group III comprises a diverse collection of 
proteins that resemble one another structurally, but not necessarily 
functionally. Bcl-2, BAG-1 and Bcl-xLprovide a cell survival function 
(Christensen et al., 1999; Stuart et al., 1998; Yang et al., 1998). However, 
Bax, which promotes apoptosis (Christensen et al., 1999) translocates to the 
mitochondrial membrane and releases cytochrome c, which can initiate the 
apoptotic cascade (for review, see Ferrer and Planas, 2003). It also competes 
for binding with Bcl-2 and with other members of the Bcl-2 superfamily of 
proteins (for review, see Ferrer and Planas, 2003). Such heterodimerization 
between anti-apoptotic and pro-apoptotic members of this family is very 
common and is considered a regulatory mechanism for the decision to 
undergo apoptosis (Reed, 1997). Thus, the balance between Bcl-2 and Bax is 
essential for the determination of the apoptotic potential of the cells, in 
which high apoptotic activity is often associated with a low Bcl-2/Bax level 
ratio (Reed, 1997). 
BAG-1 has been shown to provide an anti-apoptotic effect. Its 
overexpression in cervical cancer suppressed apoptosis both independently 
and by increasing Bcl-2 protective activity, which further increased the 
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resistance of cervical carcinoma to the effect of DNA-damaging agents 
(Yang et al., 1998; Naishiro, 1999). 
1.2.2.3 p53 
The tumor suppressor protein p53 has numerous functions (See Figure 
1.2) (Rosenthal et al., 1998). Its principle role, however, is as a 
transcriptional regulator required for the expression of a number of genes 
involved in cell cycle regulation and apoptosis. The gene encoding p53 can 
be mutated in many forms of cancer including cervical, uterine, 
adenocarcinoma, adrenal and colorectal cancers. In cervical cancer, mutation 
patterns of p53 may vary from point mutation to deletion to base-pair 
alteration, however 30% of the cases showed a higher percentage of 
Guanine-Cytosine complementary base pairs compared to the Adenine-
Thymine complementary base pairs suggesting that alteration in the base-
pairing sequence is the major mutation pattern recognized in p53 (Rosenthal 
et al., 1998). A recent clinical study showed that the overexpression ofp53 
in cisplatin-treated tumors might be associated with resistance of the tumor 
to further cell death and apoptosis (Nakayama et al., 2003). 
MDM2 is a p53-regulated protein that has a role in the translocation 
of p53 from the nucleus and enhances its proteosomal degradation (Rich, 
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Allen and Wyllie, 2000). Therefore, increased levels ofMDM-2 and 
subsequent low levels of p53 are associated with increased cell growth and 
proliferation. The p53 tumor suppressor protein can also be targeted for 
degradation by the E6 oncogene of the Human Papilloma virus (HPV), thus 
promoting neoplastic proliferations (refer to Figure 1.1) (Rosenthal eta!., 
1998). 
1.2.2.4 P ARP 
Poly (ADP-ribose) polymerase, PARP, has recently been found to 
promote cell death, but the exact mechanism of action of P ARP remains 
largely obscure. Many cellular enzymes were found to contain the P ARP 
catalytic subunit, but they have different cellular localizations (Nicoletti and 
Stella, 2003). Because PARP activation consumes much cellular energy, 
detection of abnormally high levels ofP ARP in cells might indicate 
excessive energy consumption and cellular exhaustion (for review, see Rich 
eta!., 2000). P ARP is also known as an apoptosis-inducing factor and high 
levels of P ARP are detected following DNA damage. Thus, this group of 
enzymes might also be involved in DNA repair, as well as apoptotic 
responses of the cells (for review, see Rich eta!., 2000, summarized in 
Figure 1.2). 
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Figure 1.2: Summary of the mechanism of action of the tumor 
suppressor protein, p53 (Adapted from Famuboni et al., 2002). After DNA 
damage, the tumor suppressor protein, p53, will be upregulated causing cell 
cycle arrest and enhancing DNA repair. However, in cases of irreversible 
DNA damage, p53 has been shown to transcriptionally repress the 
antiapoptotic gene Bcl-2, while it upregulates the pro-apoptotic proteins Bax 
and Fas. This in turn, promotes apoptosis. During apoptosis loss of the 
integrity of the mitochondrial membrane is followed by release of 
cytochrome c into the cytosol, this in turn leads to activation of caspase 
cleavage. Bax has been shown to contain p53-binding sites in its promoter 
site and is upregulated in response to DNA damage and increased p53. 
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1.3 Rei/NF -KB family 
1.3.1 Introduction 
The first identified member of the nuclear factor-kappa (K) B (Rel/NF-
KB) family was a protein found to be associated with a decameric 
oligonucleotide sequence in the enhancer element of the immunoglobulin 
kappa light chain in B-lymphocytes (Verma eta/., 1995; Baeuerle and 
Baltimore, 1988; Govind, 1999). The Rel/NF-KB family is now known to be 
made up of a plethora of transcriptional regulators which share a 300 amino 
acid terminal domain called the Rel homology domain (RHD) (Castranova 
eta/., 1998; Gerondakis eta/., 1999). This RHD comprises the DNA 
binding domain, nuclear localization signal (NLS), dimerization domains 
and the IKB binding domain (See Figure 1.3) (Liou and Baltimore, 1993; 
May and Ghosh, 1998). Members of this family include (Verma eta/., 
1995): 
1. NF-KB, including pSO, p65, p105 (mice devoid ofp65 generated by 
targeted "knock-out" gene disruption resulted in defects in fetal 
development localized to the spleen and liver. However, knock-out 
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mice devoid ofpl05/p50 expression showed no defects during their 
development). 
2. Lyt-10 (p100), including p100 and p52, which are required in spleen 
development. 
3. c-rel (knock-out mice showed defects in the proliferation ofB and T 
cells). 
4. relB (knock-out mice showed defects in thymus development). 
5. Dorsal, which is involved in the formation of the dorsal-ventral axis of 
the fruit fly Drosophila (Liou and Baltimore, 1993). 
Rei/nuclear factor of kappa B (NF-KB) proteins include those that do 
not require proteolytic processing and those that do require proteolytic 
processing. The first group consists of: RelA (known as p65), c-Rel and 
RelB. The second group includes NF-KB1 (known as p105) and NF-KB2 
(known as p100), which further produce p50 and p52 proteins, respectively 
(See Figure 1.3). Members of these two groups pair with each other with the 
most commonly detected NF -KB being a heterodimer of p50 and RelA. RelA 
is responsible for most ofNF-KB's transcriptional activity due to the 
presence of a strong transcriptional activation domain at its C-terminus. 
p50-c-Rel dimers are less abundant. 
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Both p50-RelA and p50-c-Rel dimers are regulated by interactions 
with the inhibitor ofKB (IKB) proteins, which cause their cytoplasmic 
localization. RelB, however, mostly associates with p 100 and the p 100-
RelB dimers are exclusively cytoplasmic. Proteolytic processing of p 1 00 
results in the release of p52-RelB dimers, which then translocate to the 
nucleus. RelB, unlike RelA and c-Rel, can function as an activator or 
repressor (May and Ghosh, 1998, Verma et al., 1998). Of the above-
mentioned proteins, only p50 and p52 are produced from the cytoplasmic 
precursors p 105 and p 100, in the presence of ATP as an energy source (May 
and Ghosh, 1998). However, the other members contain trans-activation 
domains and can act as activators or inhibitors of transcription based on 
dimers containing or lacking trans-activation domains (See Figure 1.3) (for 
review, see Beg and Baldwin 1993). 
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Figure 1.3: NF-KB and IKB proteins (Adapted from Karin eta/., 2002). A 
schematic representation of various domains in (Rel)/nuclear factor of kappa 
B (NF-KB) proteins including the Rei Homology Domain, RHD, which 
comprises the DNA binding domain, nuclear localization signal (NLS), 
dimerization domains and the IKB binding domain. (Rel)/nuclear factor of 
KB (NF-KB) proteins include those that do not require proteolytic processing 
and those that do require proteolytic processing. The first group consists of: 
RelA (known as p65), c-Rel and RelB and the second group includes NF-
KB1 (known as p105) and NF-KB2 (known as p100), which further produce 
p50 and p52 proteins, respectively. These two groups dimerize, the most 
commonly detected NF -KB dimer is p50--RelA. RelA is responsible for most 
ofNF-KB transcriptional activity due to the presence of a strong 
transcriptional activation domain. p50-c-Rel dimers are less abundant. Both 
p50-RelA and p50-c-Rel dimers are regulated by interactions with the 
inhibitor ofKB (IKB) proteins, which cause their cytoplasmic localization. 
RelB, however, mostly associates with p100 and the p100-RelB dimers are 
exclusively cytoplasmic. Proteolytic processing ofp100 results in the release 
of p52-RelB dimers, which translocate to the nucleus. RelB, unlike RelA 
and c-Rel, can function as an activator or repressor (May and Ghosh, 1998, 
Verma eta/., 1998). 
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The functions of the Rel!NF-KB family of proteins are strongly related 
to the target genes that contain the response elements for the protein (Grilli 
et al., 1993; Collins et al., 1995; for review, see Verma et al., 1995; Wang et 
al., 1999). For example, KB response elements are localized in /L-2, IL-2R, 
Ig K and MHC Classes(/) and (II) genes, and here the Rel/NF-KB family of 
proteins function in modulating the immune system responses by binding to 
these target sequences and recruiting other immune system and 
inflammatory reaction mediators (See Figure 1.4 and Table 2). However, the 
Rel/NF -KB family of proteins is also directly involved in inflammatory 
reactions and acute phase responses when the KB binding sites are found in 
the regulatory sequences for the /L-1, /L-6, TNF-a, TNF-P and serum 
amyloid A protein genes. Also, the Rel/NF-KB family of proteins is involved 
in viral infections when the KB sites are found in the HIV-LTR, SV 40, 
CMV and adenovirus. Other functions ofRel/NF-KB proteins include 
growth regulation, immune system responses and cell adhesion molecules 
(see Table 2). 
Activation ofNF-KB transcription involves the translocation ofNF-KB 
proteins to the nucleus as illustrated in Figure 1.4 (Liou and Baltimore, 
1993; May and Ghosh, 1998; Verma et al., 1995; Shain et al, 1998). The 
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factors involved in the transcriptional activation of different members of the 
Rel/NF-KB family are mentioned in Table 3 (for review, see Verma et al., 
1995; Liou and Baltimore, 1993; May and Ghosh, 1998). 
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Figure 1.4: The steps involved in the activation of NF -KB family of 
transcription factors. Activators ofNF-KB like TNF-alpha, PMA, UV or 
LPS activate the NF-KB inducible kinase, which in tum phosphorylates at 
least IKK1 (I kappa B kinase-alpha) and sometimes IKK2 (I kappa B kinase-
beta) in the I kappa B-kinase complex. Activators ofNF-KB may directly 
activate the kinase complex as well. This may be followed by 
phosphorylation of the p 1 05/p65 complex by the kinase complex, which is 
in tum followed by ubiquitination, proteasomal degradation and the nuclear 
translocation ofNF kappa B. Inside the nucleus; NF kappa B promotes the 
transcription of immune response genes. The "??????" indicates the 
possibility of lowered translocation and consequent activation ofNF-KB, 
which occurs in various diseases (Adapted from Ponnappan, 1998). 
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IKB sites iRelated functions 
IL-2, IL-2R, IgK, MHC !Immune system reaction 
Classes I and II and responses. 
IL-l IL-6 TNF -a TNF-
' ' ' 
Inflammatory reactions 
~' serum amyloid A and acute phase 
protein responses. 
HIV-LTR, SV 40, CMV, Viral infections 
adenovirus 
Rel/NF-KB family (NF- Immune system 
IKBl, NF-KB2, c-rel, !responses. 
IRelB) 
lp53, c-Myc, Ras, pRB~ ~ .. nn h regulation. 
IKB-a, IKB-y, p105, plOO IKB family members 
and Bcl-3 
I-CAM V-CAM E-
' ' 
Cell adhesion molecules 
selectin, ELAMl 
Table 2: Localization of KB binding motifs in the body suggests the 
functions ofRel/NF-KB (for review, see Verma et al., 1995; Wang et al, 
1999). 
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• Cytokines (TNF-a, IL-l, IL-2, IL-6) 
• Bacteriallipopolysaccharides 
• Phytohemagglutinin (PHA) 
• Cross-linking surface CD2, CD3, CD28 and T-cell receptors. 
• Proteins secreted by viruses, for example, tax, X, ElA 
• Viral infections, for example, HIV -1, Hepatitis B, HSV, HTL V -1 
• Antigenic stimulants for the T and B-cells receptors 
• Ultraviolet light exposure 
• X-irradiation 
• Nitric oxide 
• Hydrogen peroxide and other oxidizing agents 
• Calcium ionophores 
Table 3: The factors associated with activation of NF-KB transcription 
factor (Schottelius et al., 1999; Sun and Ballard, 1999; McFarland et al., 
1999; Liou and Baltimore, 1993; Verma et al., 1995; Kawakami et al., 1999; 
Meyskens et al., 1999; Haddad, 2002). 
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1.3.2 IKB inhibitor system 
The multiple targets of Rel/NF -KB proteins and their multiple modes 
of regulation indicate that this family possesses diversity in function. 
Interestingly, their major mode of regulation appears to be well conserved 
through the IKB inhibitor system. IKB is a protein of 60-70 kDa (Baeuverle 
and Baltimore, 1988; May and Ghosh, 1998). The IKB inhibitor system 
comprises seven molecules IKB-a, IKB-p, IKB-y, Bcl-3, p105, plOO and I KB 
R (Garcia eta!., 1999). The inhibitor of KB (IKB) kinase (IKK) complex is 
composed of two catalytic subunits, IK.Ka and IK.Kp, and one regulatory 
subunit, IK.Ky. 
The IKB inhibitor system regulates NF -KB (p50, p65) by retaining it as 
a complex in the cytoplasm (Henkel et a!., 1993). As a result, the NF-KB 
family members remain in the cytoplasm in an inactive form. In response to 
stimuli such as tumour-necrosis factor-a (TNF -a), CD40 ligand ( CD40L ), 
interleukin-1 (IL-l) or lipopolysaccharide (LPS), the IKKP subunit is 
activated, and phosphorylates the IKB proteins (bound to the NF-KB 
heterodimers) at two conserved serines. This phosphorylation event triggers 
the ubiquitin-dependent degradation of IKB by the 268 proteasome, resulting 
in the nuclear translocation of RelA-p50 (or c-Rel-p50) heterodimers and 
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transcriptional activation of target genes (See Figure 1.5). In response to 
other stimuli, such as the TNF family members lymphotoxin B (L T~) and 
BAFF, IKKa is activated to induce the phosphorylation of plOO (bound to 
RelB) at two serine residues at its carboxyl terminus. This phosphorylation 
event triggers the ubiquitin-dependent degradation of the carboxy-terminal 
half of p100, releasing its amino-terminal half, the p52 polypeptide, which 
together with its heterodimer partner, RelB, translocates to the nucleus to 
activate transcription (Garcia et al., 1999, Baeuverle and Baltimore, 1988; 
May and Ghosh, 1998, McKenzie et al., 2000) (See Figure 1.5 and Table 4). 
Rel/NF -KB family members also cooperate with other transcriptional 
regulators such as the non-Rel/NF-KB protein Ets-1. Recent data has 
provided evidence that physical interaction between Ets and NF-kappaB 
proteins is required for the transcriptional activity of the HIV -1 and HIV -2 
enhancers (Bassuk et al., 1997). These interactions represent a potential 
target for the development of novel immunosuppressive and antiviral 
therapies. 
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Figure 1.5: Illustration of the Rei/NF-KB pathway. In response to stimuli 
such as tumour-necrosis factor-a (TNF-a), CD40 ligand (CD40L), 
interleukin-1 (IL-l) or lipopolysaccharide (LPS), the IKK~ subunit is 
activated, and phosphorylates the IKB proteins (bound to the NF-KB 
heterodimers) at two conserved serines. This phosphorylation event triggers 
the ubiquitin-dependent degradation of IKB by the 26S proteasome, resulting 
in the nuclear translocation ofRelA-p50 (or c-Rel-p50) heterodimers and 
transcriptional activation of target genes (Adapted from Hiscott eta/., 2001 ). 
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Steps involved in Rel/NF -KB activation 
1. Exposure to a stimulus that activates NF-KB such as UV light. 
2. Degradation ofiKB or its inactivation by phosphorylation by means of 
protein kinases (McKenzie et al., 2000). 
3. Dissociation of the complex between NF-KB family members and IKB 
inhibitor system. 
4. Translocation ofNF-KB proteins to the nucleus. 
5. DNA binding ofNF-KB proteins. 
6. Transcriptional induction by NF-KB proteins. 
Table 4: Steps involved in Rei/NF-KB activation (Shain et al., 1998) 
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1.3.3 Role of NF -KB in apoptosis and cell survival. 
The dual role of NF -KB in enhancing or inhibiting apoptosis and cell 
death has attracted much attention in regard to its role in carcinogenesis 
(Mercurio and Manning, 1999; Tickle, 1998; Sonenshein, 1997; Muller et 
al., 2003; Bushdid et al., 1998; Huang et al., 2000; Romano et al., 2000; 
Bukowski et al., 1998; Bash et al., 1999). 
1.3.3.1 NF -KB involvement in apoptosis 
The role of Rel/NF -KB proteins in apoptosis has been well studied 
(Hoger linden et al., 1999; Manna et al., 2000). NF -KB, for instance, was 
found to be activated following TNF-a-induced apoptosis in several cell 
lines (Miyamoto et al., 1994). Treatment of cell lines derived from acute B-
cell leukemia and human thymocytes with etoposide was found to activate 
NF -KB and this activation occurred prior to the initiation of apoptosis (Beg 
and Baldwin, 1993). Further evidence supporting the involvement ofNF-KB 
in apoptosis is the presence ofNF-KB binding sites in the genes encoding IL-
1/3 converting enzyme protease, c-myc, and TNFa, which are all involved in 
apoptosis and cell death (Collins et al., 1995; Beg and Baldwin, 1993). Also, 
several studies showed that p65 is involved in apoptosis. This was based on 
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an original observation whereby inhibition of apoptosis was achieved by 
overexpression of a dominant-negative p65 protein (Higgins et al., 1993). 
1.3.3.2 Rei/NF-KB role in cell protection and survival. 
The role of Rel/NF -KB proteins in cell survival is generally associated 
with their ability to upregulate the expression of myc (for review, see Foo 
and Nolan, 1999; Chen et al., 1998). Myc is a protein that mediates the 
transcriptional activation of cyclin A and cyclin D3, which are cell cycle 
regulators. A decrease in the myc protein concentration in the cell has been 
associated with apoptosis. Another pathway that leads to high myc levels is 
through the stimulation of CD40, a member of TNF receptor family, which 
results in NF-KB activation (Madrid et al., 1999; Furman et al., 2000) and 
whose stimulation has been implicated in cell survival and protection 
(Madrid et al., 1999). 
The role of Rel/NF -KB as a factor in both cancerous and normal cell 
survival is well documented. Recent results, for instance, have shown NF-
KB to be activated in the early malignant transformation of mammary cells 
of the breast (Kim et al., 2000). Furthermore, NF-KB is constitutively active 
in pancreatic adenocarcinoma in humans (Wang et al., 1999), in T-cell 
leukemia cells (Mori et al., 1999), in human breast cancer (Cogswell et al., 
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2000) and in head and neck squamous cell carcinoma cell lines (Ondrey et 
al., 1999). 
In non-cancer cells, NF-KB was reported to be essential for the growth 
and survival of sympathetic nerve cells independently of the de novo protein 
synthesis (Maggirwar et al., 1998). Further evidence of severe liver 
degeneration was associated with lack ofNF-KB activation (Rudolph et al., 
2000). This was based on the death of murine embryonic fibroblasts that 
lack detectable NF-KB DNA binding activity in response to TNF-a, LPS, IL-
l and do not show IKB kinase activity required for NF -KB activation 
(Rudolph et al., 2000). 
The anti-apoptotic activity of Rel/NF -KB can be regulated by other 
proteins. For instance, the X chromosome-linked inhibitor of apoptosis 
(XIAP) induces NF -KB activation by increasing the nuclear translocation of 
its p65 subunit (Hofer-Warbinek et al., 2000; Stehlik et al., 1998). In 
addition, CD95, which is known as Fas and possesses an apoptotic effect, 
was found to stimulate NF-KB degradation by caspases (Ravi et al., 1998), 
but when an antibody against CD95 was used, caspases were inhibited and 
the inducibility ofNF-KB was restored (Ravi et al., 1998). 
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1.3.4 Xrel3 
Xre/3 encodes an embryonic protein found to be related to the rel 
family of proteins. The Xre/3 gene is present in the genome of the 
amphibian, Xenopus laevis and is expressed in and is essential for the 
normal development of the head of Xenopus laevis embryos (Lake et al., 
2001 ). Xre/3 is also normally expressed in the otocysts and notochord of the 
embryonic larval stages (Lake et al., 2001). Interestingly, Xrel3 
overexpression has been implicated in the development of epidermal tumors 
in embryos (Yang et al., 1998; Lake et al., 2001), but little is known about 
how these tumors form, or whether they have similar properties to human 
tumors. Therefore, I was interested in investigating whether the Xrel3 
protein had properties that could contribute to human cancer. By applying 
what is known about the role of Xrel3 in embryos to human cell lines, it may 
be possible to uncover new knowledge about the mechanism of Rel/NF -KB 
activity in general. I considered this to be a novel approach to the study of 
this important family of oncogenes. 
In addition to its ability to cause embryonic tumor formation, the 
rationale for studying the effects of Xrel3 in human cervical cancer cells has 
basis in practicality. When a DNA vector encoding tagged-Xrel3 was 
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transiently transfected into HeLa cells, Xrel3 protein constitutively localized 
in the nuclei, suggesting its ability to be active constantly in mammalian 
cells (Green, 2003). In addition, HeLa cells do not normally express Rel/NF-
KB, so the transfection of Xrel3 into these cells gave me the opportunity to 
study the activity of an interesting Rel/NF -KB protein in a negative 
background. Therefore, even though Xrel3 is not a mammalian gene, its 
homology to the mammalian Rel/NF -KB family indicates that it may serve 
as a good model for gene regulation by this family enabling us to understand 
the mechanism of action of the Rel/NF-KB family of transcriptional 
regulators in cancer cells. 
1.4 Cancer Chemotherapy 
1.4.1 Introduction 
Many chemical agents are used in the treatment of cancer. Some can 
be used alone in single therapy and others have to be combined or added to 
other regimens for an effective outcome. The five groups of single 
chemotherapeutic agents are: alkylating agents, antimetabolites, plant 
derivatives, antitumor antibiotics and the miscellaneous group which 
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contains the platinums, procarbazine, mitotane and gallium nitrate (British 
Medical Association, 2002). 
1.4.2 Platinums 
The platinum-containing compounds are carboplatin, cisplatin and 
oxaliplatin. This group of chemotherapeutic drugs is very effective in 
monotherapy regimens (Gadducci et a!., 1997). They are the most active 
agents in the treatment of ovarian and cervical cancers. However, they are 
associated with three major drawbacks (Reedijk, 2003): 
1. Severe toxicity in the form of nephrotoxicity, ototoxicity, 
myelosuppression and peripheral neuropathy. 
2. Narrow range of tumors upon which they are effective. 
3. The development of resistance after a short period of treatment. 
New approaches are now designed in an attempt to expand the 
mechanism of action of platinums. This is done by developing a new 
generation of platinum-containing compounds that exhibited a broader 
spectrum of activity on different tumors, lower toxicity potential as well as 
delayed resistance to treatment (Fuertes eta!., 2002; for review, see Jakupec, 
2003). 
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1.4.3 Cisplatin 
Cis Diamminedichloroplatinll (cisplatin) is one of the platinum-
containing anti-cancer agents. It can be recognized from its chemical name 
that the cis form is the active form of the drug. The trans form was found to 
possess no biologic activity (Reedijk, 2003). The mechanism of action of 
cisplatin is similar to the alkylating agents, but it is not identical. Cisplatin 
works by promoting DNA cross-linking and chelation (United States 
Pharmacopeia, 2003). Recent clinical studies have shown that improved 
cytotoxicity of cisplatin can be attained by increasing the exposure time of 
the tumor to the drug (Markman, 2003 ). 
1.4.4 Rei/NF -KB and Chemoresistance 
Many researches have attempted to investigate the role that NF -KB 
family might have in chemotherapeutic resistance. Activation of the Rel/NF-
KB was found to be associated with chemotherapeutic resistance by 
suppressing the apoptotic potential of the chemotherapeutic drug. Recent 
data demonstrate that the protection from apoptosis induced in response to 
carbonyloxycamptothecin (CPT-11) treatment is effectively inhibited by the 
transient inhibition ofNF-KB in a variety ofhuman colon cancer cell lines 
(Cusack et al., 2000). This might be due to the cell survival effects 
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associated with the upregulation ofReliNF-KB family as previously 
mentioned. In addition, genetic manipulation aimed at inhibiting Rel/NF -KB, 
was found to cause sensitization of different tumor cells, like lung cancer 
cells, to the effect of chemotherapeutic drugs (Jones eta/., 2000). This 
makes the Rel/NF-KB family an attractive set of proteins to study in 
chemoresistant tumors. 
1.5 Purpose and hypothesis of this study 
Several attempts are being made to find solutions for the resistance 
encountered by the usage of chemotherapeutic drugs. An investigation of the 
upregulation of NF -KB might be a promising field of study in this regard 
since Rel/NF -KB activation has been associated with chemoresistance. 
Cisplatin can be used as a monotherapy without any adjuvant 
chemotherapeutic drugs. Cisplatin is also used in the treatment of 
gynecologic cancers like ovarian cancers (Gudducci et al., 1997; Reedijk, 
2003). Previous studies have shown that the apoptotic effect induced by 
chemotherapy in cervical cancer involves p53 and the HPV -E6 oncogenes 
and might be enhanced or attenuated depending on the platinum earner 
ligand (Koivusalo et al., 2002). 
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The purpose of this study was to investigate the effect of Xre/3 
overexpression on the growth of HeLa cells with and without 
chemotherapeutic treatment. The proposed hypothesis is that Rel!NF-KB is a 
cause of chemotherapeutic resistance encountered in cancer cells. 
My objectives were: 
1. To create an inducible Xre/3 model system to study its role in cancer 
chemoresistance. The Tet-On system was used to induce the expression of 
Xre/3 inserted downstream from the Tet promoter, by the addition of 
doxycycline in HeLa cells. 
2. To determine the effect ofinducedXrel3 expression on the growth of 
HeLa cervical cancer cells. 
3. To determine the effect ofinducedXre/3 expression on the growth of 
HeLa cells treated with cisplatin. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Materials 
Tissue culture supplies including 6-wells plates, 100 mm tissue 
culture plates, 1.5 ml and 2 ml eppendorf tubes were all purchased from 
Fisher Scientific Co. Dulbecco's modified Eagle medium (DMEM), fetal 
calf serum; trypsin-ethylenediamine tetraacetic acid (EDTA), genaticin and 
hygromicin were all purchased from Invitrogen. HeLa cells were purchased 
from ATCC. Fisher Scientific Co supplied the eppendorf microcentrifuge 
test tubes for PCR. 
RNeasy Mini kit for isolation of total RNA from animal cells, DNeasy 
kit for DNA extraction from cultured animal cells, Effectene Transfection 
kit, QIAprep spin Miniprep kit for plasmid extraction from bacteria and 
Quiaquick Gel Extraction kit for DNA extraction from agarose gels were 
purchased from Qiagen. 
Taq DNA polymerase, dNTP and 10 x Buffer, which were used in 
PCR, were purchased from Qiagen. The ECL system and Hybond 
nitrocellulose membrane (Amersham) were used for western blotting. The 1 
kb DNA ladder marker, the low melting point agarose, agarose and 
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acrylamide were purchased from Invitrogen. The Carnation skim milk 
powder was used for western blotting as a blocking agent. Cisplatin was 
purchased from Sigma Chemical Co. and X-ray film was purchased from 
Kodak. 
Mouse anti-BAG-1 monoclonal antibody (mAb) was established in 
our laboratory (Yang et al, 1998). Mouse mAbs for Bcl-XL, Bcl-2, p21, p53, 
caspase-3, Cruz marker and secondary anti-mouse antibodies were 
purchased from Santa Cruz Biotechnology. Mouse mAbs for BAX, PCNA, 
MDM-2, HPV 16/18-E6 were purchased from Oncogene Co., while mouse 
mAbs for P ARP and caspase-8 were purchased from PharMingen. Sigma 
Chemical Co. supplied anti-~ actin; however Amersham Co. supplied the 
Rainbow protein marker. 
2.2 Methods 
2.2.1 Cell culture 
All HeLa cells were maintained at 3TC in the presence of 5% C02 in 
a humidified incubator. When the cells reached 80% confluency, the 
medium was aspirated, the cells were washed with warmed PBS and the 
washings were aspirated. The cells then were incubated for 15 minutes with 
2 ml trypsin-EDT A to detach the cells from the culture dish followed by the 
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addition of 8 ml DMEM to avoid further cell lysis and pipetting the mixture 
several times to ensure even distribution of the cells. The cells were passed 
to fresh culture dishes at different concentrations e.g 1 :5, 1:10 and 1 :20 
according to the purpose of the experiment. HeLa-Tet On cells were 
recovered from frozen stock and maintained in DMEM containing 10% FCS 
and 0.03% genaticin until transfection. 
After transfection with pTRE2 and pTRE2-Xrel3, cells were 
maintained in a selective medium containing DMEM + 10% FCS + 0.03% 
genaticin + 0.02% hygromicin. 
The cell numbers were counted with a hemocytometer. The above 
steps were done during regular passage of the cells where the cells were 
usually passed at 1 :20, 1:10 or 1 :5 into fresh plates. Also before growth 
assays, the above steps were repeated where 2 x 104 cells were seeded in 
each well of the 6 wells plate and the cell numbers were counted with a 
hemocytometer daily for 6 days. 
2.2.2 Construction of the pTRE2-Xrel3 plasmid 
2.2.2.1 Polymerase chain reaction (PCR) 
PCR was performed to amplify the Xrel3 gene. The protocol provided 
by Qiagen was followed. The Gene Amp PCR system 2400 was 
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programmed to run for 30 cycles as follows: 94°C for 3 minutes, 94°C for 1 
minute, 61 oc for 1 minute, 72°C for 10 minutes and 4°C for 1 hour. 
2.2.2.2 DNA extraction and purification from agarose gel 
1% agarose gel was prepared in 30 ml 5 x TBE buffer. The 
electrophoresis apparatus was run for 45 minutes. 
The Xrel3 band, which corresponds to 1.6 kb, was clearly identified 
under U.V light by the Eagle Eye II still video system (Stragagene). This 
DNA fragment was excised under UV light and then the DNA was extracted 
by means of the QIAquick gel extraction kit using a vaccum manifold 
according to the manufacturer's instructions. 
2.2.2.3 Restriction enzyme cleavage of pTRE2 and pTRE2-Xrel3 
plasmids 
The map ofthe pTRE2 vector (Figure 2.1) shows the restriction sites 
BamH I and Xba I that are targeted by the BamH I and Xba I restriction 
enzymes. 
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2.2.2.4 Ligation 
The protocol supplied by Invitrogen was followed according to the 
manufacturer's instructions. 
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Figure 2.1: The map of the pTRE2 vector showing the restriction sites 
(BamHI and Xbal) where Xrel3 was integrated (Adapted from Cion tech, 
2003). 
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2.2.2.5 Transformation of E. coli with pTRE2-Xrel3 plasmid. 
The protocol supplied by Clontech lab, Inc was followed with specific 
modifications. In brief, thawed E.coli competent cells were added to 10 ng 
of the ligated pTRE2-Xrel3 plasmid solution. This was followed by 
incubation on ice for 30 minutes, heat shocking in a 42°C water bath for 60 
seconds and chilling on ice for 2 minutes. Then, 500 f..ll LB broth were added 
followed by 1-hour incubation at 37°C on a shaker. The solution was then 
spread on ampicillin containing LB agar plates and incubated at 3 7°C 
overnight. 
2.2.2.6 Plasmid purification using QIAprep Spin Miniprep kit. 
The single colonies of bacteria growing on the ampicillin plates were 
allowed to propagate by incubating each single colony in 50 ml LB broth at 
3 7°C overnight. The protocol provided by Qiagen kit was followed 
according to the manufacturer's instructions. 
2.2.2. 7 Verifying the presence of Xrel3 
To confirm the presence ofXrel3 in the extracted DNA from the 
previous step, PCR was used, as previously described. The amplicon was 
then sequenced commercially. 
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2.2.3 Establishing stable transfection of HeLa cells with Xrel3 
HeLa Tet-On cells, which had been previously established in our lab, 
were recovered in DMEM + 10% FCS in the presence of 0.03% genaticin. 
HeLa Tet-On cells were transfected with pTRE2-Xrel3 plasmid and pTRE2 
vector, which served as a control. The Effectene Transfection kit protocol 
was followed according to the manufacturer's instructions. The controls 
used were the pTRE2 vector and the non-transfected HeLa cells. 
After 48 hours, DMEM + 10% FCS + 0.03% geneticin + 0.02% hygromicin 
was added to each petri dish to serve as a selective medium. The 
hygromycin resistance gene inserted in the control pTRE2 vector and 
pTRE2-Xrel3 plasmid offered selective advantage to those cells harboring 
these plasmids. Conversely, HeLa Tet-On cells not containing pTRE2 or 
pTRE2-Xrel3 plasmid were killed after 24 hours by the effect ofhygromicin 
selective medium. 
2.2.4 Selection of the stably transfected clones. 
After transfection, the colonies containing pTRE2 vector and pTRE2-
Xrel3 plasmid were selected using the micro-glass cylinder method. After 
reaching 80% confluency, cells from each separate colony were transferred 
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to a separate well of 24-wells plates then 6-wells plates, and after incubation 
to a 1 00 mm petri dish. 
2.2.5 Verifying the presence ofpTRE2-Xrel3 and pTRE2 in the selected 
clones. 
2.2.5.1 DNA extraction from cultured cells 
The protocol provided by the DNeasy kit purchased from Qiagen was 
followed. 
2.2.5.2 Polymerase chain reaction 
To test for the presence of Xrel3, amplification for both clones 
selected (clones containing pTRE2 vector and those containing pTRE2-
Xrel3 plasmid) was performed as previously described. This was followed 
by electrophoresis on a 1% agarose gel and identifying the Xrel3 band at 1.6 
kb in the clones containing the pTRE2-Xrel3 plasmid and its absence in the 
clones containing the pTRE2 vector. 
2.2.6 Verification of Xre13 transcription 
2.2.6.1 RNA extraction 
The protocol used the RNeasy kit supplied by Qiagen according to the 
manufacturer's instructions. Then elution of the RNA was performed by 
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centrifugation with 50 J.Ll RNase-free water. The concentration of RNA in 
each sample was determined spectrophotometrically. 
2.2.6.2 Confirming the integrity of the extracted RNAs. 
RNase-free environment was strictly adhered to throughout the 
experiments dealing with RNA. The RNA samples ( 1 J.Lg of each sample) 
extracted previously were mixed with 2 J.Ll of RNA loading buffer and 
loaded into the wells of a 1% agarose gel mounted into an electrophoresis 
apparatus. The gel was prepared as described previously, but using specific 
RNase-free agarose and sterile water. 
2.2.6.3 Northern blotting 
To prepare the sample, 20 J.Lg of each RNA sample were heated for 15 
minutes at 65°C for denaturing and then placed on ice immediately. The 
RNA samples were mixed with 5 J.Ll RNA loading buffer. 
Gels were prepared using, 850 mls of running buffer 10 x MOPS. Each 
formaldehyde gel was prepared by boiling 1.3 g agarose gel in 120 mls 
sterile water accounting for the water that will be evaporated after which 30 
mls of 3 7% formaldehyde were added. The first well used as a marker was 
separated and stained with ethidium bromide. Transferring the RNA onto a 
50 
membrane was performed overnight. This was followed by fixing the RNA 
onto the membrane by baking the membrane in an oven at 80°C for 2 hours. 
To label the probe, Xrel3 DNA was prepared by resolving by 
electrophoresis the Xrel3 amplified plasmid and then extracting the Xrel3 
DNA band using the QIAquick gel extraction kit described previously. 30 ng 
of the probe were used and labeled according to the manufacturer's 
instructions. 
For prehybridization, 8 ml of pre-warmed 65°C prehybridization solution 
was added to the membrane in the hybridization bottle with the RNA side 
facing the solution. The bottle was rotated for 30 minutes in a hybridization 
oven adjusted to 65°C. 
For hybridization, 1.6 x 106 cpm/ml of hybridization buffer is required to 
ensure adequate probe labeling. The amount of the probe required for 
hybridization was boiled for 1 0 minutes, chilled on ice immediately for 5 
minutes then poured into 45 ml orange-capped tubes in the 65°C water bath. 
The rotating hybridization bottle after 30 minutes was emptied from the 
prehybridization solution and filled with pre-warmed 65°C prehybridization 
solution. The hybridization bottle was rotated in the hybridization oven for 2 
hours at 65°C. The blot was washed to high stringency using 492.5 ml sterile 
51 
water, 2.5 ml 20 X sse and 5 ml of 10% SDS for several times at 65°C and 
exposed to X-ray film at -70°C overnight. 
2.2.7 Growth rate and saturation density assay. 
Transfected HeLa Tet-On cells with either the pTRE2 vector or the 
pTRE2-Xrel3 plasmid were grown exponentially. 2 x 104 cells were seeded 
per well of a 6-well plate. The cell numbers were counted daily for 6 days 
using a hemocytometer. This was done for the pTRE2-Xrel3-transfected 
cells with and without the presence of doxycyline, which induces Xrel3 
expression. Also it was done concomitantly for the pTRE2-transfected HeLa 
cells with and without doxycycline to serve as a control. 
2.2.8 Drug treatment 
2 x 104 cells were seeded in each well of a 6-wells plate. The 
following day, 1 J..Lg/ml doxycycline was added to one and not to another 
plate seeded with pTRE2-Xrel3-transfected HeLa cells and the same was 
done for pTRE2. Transfected HeLa cells with either pTRE2 or pTRE2-
Xrel3 were treated with various concentrations of cisplatin (0.5 J..LM, 1 J..LM 
and 2 J..LM) from 4 J..LM cisp1atin stock solution in sterile water. Cell numbers 
were taken after 2 hours of adding the cisplatin. The addition of fresh 
cisplatin was repeated daily for 6 days. The average of four independent 
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experiments was plotted. However, the same experiment was repeated 2 
more times with the addition of fresh cisplatin every other day. 
2.2.9 Cell viability assay 
Cell viability was assessed for both pTRE2-Xrel3 transfected cells 
and pTRE2 control cells with, without doxycycline and with and without 
cisplatin by trypan blue dye exclusion. Approximately 2 x 104 cells/well 
were seeded in 6-wells plates. After 24 hours, the cells were trypsinized with 
500 Ill trypsin then 500 !J.l of 4% trypan blue was added and mixed gently. 
Then under the light microscope, the viable cells appeared clear and 
transparent because they were unstained by the dye, however dead cells 
appeared blue. The number of viable cells was counted daily for 6 days. 
2.2.1 0 Western blotting 
Proteins were extracted from 90% confluent cells transfected with 
both pTRE2-Xrel3 and pTRE2 control cells in the presence and absence of 
doxycycline, with and without cisplatin. Briefly, the cells were washed with 
cold PBS to remove the medium, scraped off the petri dish using 300 !J.llysis 
buffer, and transferred to eppendorftubes and left on ice for 30 minutes. 
This was followed by microcentrifugation at 4 °C for 1 0 minutes. The 
supernatant was transferred to a clean eppendorftube and stored at -70°C. 
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The concentration was determined using the DC Lowry protein assay kit 
(Bio-Rad) as advised by the manufacturer. Protein extracts, usually 30 f..Lg, 
were mixed with equal volumes of 2 x SDS-polyacrylamide gel 
electrophoresis (PAGE) gel loading buffer (200 mM Tris-HCl (pH 6.8), 4% 
SDS, 0.2% bromophenol blue, 20% glycerol), boiled for 3 minutes, chilled 
on ice and resolved in an SDS-PAGE gel. Protein samples were run on a 
discontinuous 12% polyacrylamide gel, pH 8.8 according to Yang's 
protocol. Gels were equilibrated in Towbin transfer buffer (25 mM Tris, 
20% methanol, 192 mM glycine) for 15 minutes. The proteins were 
transferred to a Hybond nitrocellulose membrane at 20 V for 45 minutes 
using a Trans-Blot SD transfer apparatus (Bio-Rad). After transferring, the 
membranes were blocked in 5% skim milk powder in TBST prepared by 
mixing 20 mM Tris/HCl (pH 7.6), 137 mM NaCl, 0.1% Tween 20 for 1 hour 
on a shaker at room temperature. The membranes were then incubated with 
the primary antibody, at the concentration recommended by the 
manufacturer, in 5% skim milk powder in TBST overnight at 4°C on a 
rotator, followed by washing the membrane thrice with TBST for 10 
minutes, incubating with the secondary antibody for 1 hour at room 
temperature, washing thrice with TBST for 10 minutes, detecting the signals 
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using the enhanced chemilumiscence (ECL) system and exposing the ECL 
film as advised by the manufacturer. The signals were stripped off the 
membrane by shaking the membrane with the stripping buffer (1 00 mM 2-
mercaptoethanol, 2% SDS, 62.5 mM Tris/HCl, pH 6. 7) at 50°C for 30 
minutes, followed by rinsing the membranes thrice with TBST for 10 
minutes each time, blocking, and reprobing with ~-actin mAb and following 
the previously explained steps. The density of the bands was quantified 
using the Eagle Eye II Still Video system (Stratagene ). 
2.2.11 Statistical Analysis 
The statistical analysis was performed using Student's t-test. 
Differences of p<0.05 were considered to be significant (See Appendix 1 ). 
Also, the graphs and histograms were generated using the Sigma plot 
program and Excel of Microsoft Office. 
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CHAPTER 3 RESULTS 
3.1 Xre13 expression in HeLa cells transfected with pTRE2-Xrel3 
plasmid 
The Xre/3 coding region (bases 1 to 2251) was ligated into pTRE2 
and stably transfected into HeLa-tet On cells. I selected 15 colonies, which 
were transfected with the pTRE2-Xrel3 plasmid and 4 colonies transfected 
with pTRE2 vector alone as a control. DNA from cells of all the 19 colonies 
was extracted. I then amplified the transgene in the entire DNA extract by 
PCR to determine if the pTRE2-Xrel3 plasmid was successfully integrated 
into the genome. The PCR products were first cleaved with BamHI and Xbal 
restriction enzymes and then loaded into the wells of a freshly prepared 1% 
agarose gel and resolved by electrophoresis. 
The results showed that the transgene was present in the 15 colonies 
selected after transfection with pTRE2-Xrel3 plasmid and this was 
confirmed by the presence of the band at 1.6 kb, which corresponds to the 
size of the Xrel3 gene, however no Xrel3 gene was detected in the 4 colonies 
transfected with pTRE2 vector (Figures 3.1 A and B). In DNA from the 
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colonies transfected with the pTRE2 vector, a band was clearly seen at 3.8 
kb, which corresponds to the size of the transfected pTRE2 vector. 
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Figure 3.1: A) Xrel3 expression in pTRE2-Xrel3 transfected HeLa cells. 
The upper panel shows the presence of Xrel3 band at 1.6 kb in the selected 
colonies designated by numbers from 1 to 10 as indicated on the top of the 
figure. The lower panel shows the presence of Xrel3 in the remaining 
colonies designated by numbers 11, 12, 13, 14 and 15 as indicated on the top 
ofthe figure. 
B) Absence of Xre13 in the pTRE2 transfected HeLa cells. The upper 
panel shows the different samples loaded as indicated on top of the figure. 
Starting from the left hand side, the sample wells were loaded with the 
original sequenced plasmid, colony 10 and 11 transfected with pTRE2-Xrel3 
plasmid and colonies 1, 2 and 3 transfected with pTRE2 vector. The lower 
panel shows the rest of the samples loaded as indicated on top of the figure. 
Starting from the left to the right, the sample wells were loaded with the 
original sequenced plasmid, colony 1 and 2 transfected with pTRE2-Xrel3 
and colonies 2, 3 and 4 transfected with pTRE2 vector. 
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3.2 Verification of the size of Xre13 gene in the transfected He La cells 
To further confirm that the size of the Xrel3 transgene was not altered, 
I amplified the Xre/3 gene sequence alone directly from each of the colonies 
I obtained. The results showed that the size of a band, which appeared upon 
Xrel3 amplification from the transfected HeLa cells, coincided with Xrel3 
amplified from the original plasmid (Figure 3.2). Thus, the size of the 
inserted Xre/3 sequence was similar to that of the original plasmid. 
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Figure 3.2: Verification of the size of Xrel3 gene inserted in the pTRE2-
Xrel3 plasmid following transfection in BeLa cells. Amplification of 
Xrel3 in the extracted DNA was performed using PCR as described in the 
Materials and Methods. A clear band of the size of 1.6 kb, coinciding with 
the size of the Xrel3 gene inserted and amplified, was seen in all the 
samples. The Xrel3 band, which appeared upon amplification of the gene in 
the transfected cells, is of the same size as the Xrel3 band, which appeared 
upon amplification of the gene in the original sequenced plasmid. 
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3.3 Induction ofXrel3 expression in transfected HeLa cells by 
doxycycline. 
In order to determine whether Xrel3 expression could be induced in 
the HeLa-Tet On cells transfected with pTRE2-Xrel3, I performed Northern 
analyses of RNA extracted from both pTRE2-Xrel3 transfected HeLa cells 
and pTRE2 transfected HeLa cells in the presence or absence of 
doxycycline. The integrity of the extracted RNAs was verified by the 
presence of the 288 and 188 bands of comparable intensities (Figure 3.3). 
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Figure 3.3: Verification of the integrity of extracted RNAs for Northern 
blotting. 
RNA samples show 2 equal bands corresponding to 18S and 28S ribosomal 
subunits. The numbers represent the number of colonies from 1 to 15 
transfected with pTRE2-Xrel3. The letters represent the 4 control colonies 
transfected with pTRE2 vector. 
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3.4 Northern Analyses 
Based on the results of the Northern blots, I selected the best clones 
(those that showed a clear signal upon induction and no signal without 
induction) to work with. The results were as follows: 
1. Transcription of Xre/3 was evident in all of the clones with pTRE2-Xrel3, 
only after induction by doxycycline (1 J-Lg/ml) (Figure 3.4). 
2. The clones with the pTRE2 vector didn't show any transcription of Xre/3 
with and without induction by doxycycline (Figures 3.4 and 3.5). This was 
determined by the absence of any band at the expected size of Xre/3 mRNA. 
3. The total cellular RNA extracted from colony number 15, which was 
transfected with pTRE2-Xrel3 plasmid, failed to show any transcription for 
Xre/3 gene after induction by doxycycline (Figure 3.4). This result indicates 
that colony number 15 does not express Xre/3. 
4. Colonies numbers 1, 5, 7, 8, 9 and 11 showed leaky transcription ofXre/3 
in the absence of doxycycline, which means that Xre/3 trans gene in these 
cases might be inserted in a location on the heterochromatin that is of high 
transcriptional activity in the absence of doxycycline (Figure 3 .5). 
5. Colonies number 2, 4, 6 and 10 showed non-specific signal (Figure 3.5). 
This is manifested by the appearance of a band in addition to the one 
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corresponding to theXrel3 mRNA (colonies 2, 4 and 10) and sometimes the 
appearance of only one band, but of different size (colony 6). 
6. However, colonies number 3, 12, 13, and 14 showed no signal at all 
without induction and a clear signal after induction by doxycycline. These 4 
clones showed different levels of Xrel3 activation (3 > 13 > 12 > 14) and were 
selected for further study (Figure 3.6). 
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Figure 3.4: Northern blot analysis of total cellular RNA extracted from 
doxycycline-treated pTRE2-Xrel3 colonies designated by the numbers 1 
to 15 and control pTRE2 colonies given the numbers 1 and 2. 
The upper panel shows the transcription of Xrel3 upon induction by 
doxycycline in the pTRE2-Xrel3 transfected colonies designated by the 
numbers 1 to 7. The first 2 wells were loaded with induced pTRE2 vector, 
which served as a control. 
The lower panel shows the transcription of Xrel3 upon induction by 
doxycycline in the pTRE2-Xrel3 transfected colonies designated by numbers 
from 8 to 14, but not colony 15 (see text). The first well was loaded with an 
induced pTRE2 vector to serve as a control. The blots were repro bed with 
actin to monitor loading of RNA samples. 
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Figure 3.5: Northern blot analysis of total cellular RNA extracted from 
the non-doxycycline treated pTRE2-Xrel3 transfected colonies 
designated by the numbers 1 to 14. Both blots were reprobed with 
GAPDH, a housekeeping gene, which serves as a normalization control. The 
X-ray films were exposed for 18 hours at -70°C. 
The upper panel shows Northern blot analysis of the colonies 
designated by numbers 1 to 6. 
A) The effect of+/- doxycycline for colony 1 and 2 was examined. 
B) Leaky Xrel3 transcription was observed for colony 1 and 5 in the 
absence of doxycycline, while an unknown band appeared for colony 2. 
C) Colonies 3 and 4 showed no signals without induction, while colony 6 
showed a non-specific signal. 
D) This was compared to the pTRE2 vector, which showed no signals 
with or without doxycycline. 
The lower panel shows the Northern blot analysis of the remaining 
colonies designated by the numbers 8 to 14. 
A) Colonies 7 and 8 showed leakage Xrel3 transcription without 
doxycycline. 
B) Colonies 9, 10 and 11 showed faint signals at the same size ofXrel3. 
C) However, colonies 12, 13 and 14 showed no signals at all without 
doxycycline. 
70 
=' 0 
=' I 
~ >< 
Ol 
11 ><tO CD 11 CD 
1-' ~ CD C'l Ill w 1-' f-1· ~ ~ I Hl Ill w f-1· (l 
I ~ pTRE2-Xrel3(colony7) I t t -...) I pTRE2-Xrel3+dox(colony8) '• pTRE2 - I pTRE2-Xrel3(colony8) pTRE2-Xrel3+dox(colonyl) I pTRE2-Xrel3(colony9) I I pTRE2-Xrel3(colonyl) 
I pTRE2-Xrel3(colonylO) t I I pTRE2-Xrel3+dox(colony2) 
I pTRE2-Xrel3(colonyll) I 
,, pTRE2-Xrel3(colony2) 
• 
pTRE2-Xrel3(colony12) I pTRE2-Xrel3(colony3) 
' 
- I I pTRE2-Xrel3(colony4) pTRE2-Xrel3(colony13) 
I pTRE2-Xrel3(colonyl4) I 
' 
pTRE2-Xrel3(colony5) 
I • pTRE2-Xrel3(colony6) 
Figure 3.6: Confirmation of Xrel3 inducible expression in selected 
clones. 
The upper panel shows Northern blot analysis of colonies 3,12,13 and 14, 
which were selected because they showed no signal at all without 
doxycycline and showed signals of varying intensity with doxycycline. 
The lower panel shows the corresponding densitometry analysis of the 
results. 
Based on the optical density of the individual signals after normalization 
with GAPDH, clone 3 was designated the highest expressing clone, clone 14 
was designated intermediate expressing clone and clone 12 was designated 
the lowest expressing clone. Xrel3 transcription was quantified by 
measuring the optical density of the bands after 18 hours exposure. The 
numbers from 1 to 9 underneath the columns in the lower panel designates 
the number of columns. 
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3.5 Growth Assay 
Approximately 4 x 104 cells of each ofthe highest (clone 3), 
intermediate (clone 14) and lowest (clone 12) Xrel3 expressing clones were 
seeded per well in a 6-wells plate. Only one of the 2 plates was treated with 
doxycycline (1 J.!g/ml). This was done concomitantly for both the pTRE2-
Xrel3 transfected cells and the control cells transfected with just the empty 
vector. Results showed that the expression ofXrel3 caused a delay in the 
normal growth of cells. This delay in growth started to appear on the third 
day of the experiment in all the clones examined (highest, intermediate and 
lowest-level expressing clone). This effect was absent in the non-induced 
pTRE2-Xrel3 clones as well as in the control cells. However, clone 14 
showed the greatest cellular growth suppression response to Xrel3 induction 
and was focused on in the future experiments (Figure 3. 7). This clone 14 
was renamed pTRE2-Xrel3 (Int.). 
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Figure 3.7: Growth Assay for the highest, intermediate and lowest 
Xre13-expressing clones +/- doxycycline. The graph represents the number 
of cells growing per well versus the number of days. Approximately 4xl 04 
cells were seeded/ well in 6-wells plates. Results show that following 
induction of Xrel3 expression by doxycycline at day 1, a decline in the 
growth rate was observed as compared to the non-induced pTRE2-Xrel3 
transfected cells. The growth rate was not changed+/- doxycycline in the 
pTRE2 control HeLa cells, which served as a control. The intermediate 
level-expressing clone showed the greatest variation in the growth rate+/-
induction as determined 5 and 6 days following induction. These results 
represent the mean ± standard deviation of 6 independent experiments. The 
bars represent the mean ± standard deviation. Xrel3 expression caused a 
statistically significant decline in the growth rate. Figure A shows the 
difference in growth between the non-induced and induced state of the 
highest level-expressing clone as compared to the non-induced and induced 
state of the empty vector. 
Figure B shows the difference in growth between the non-induced and 
induced state of the intermediate level-expressing clone as compared to the 
non-induced and induced state of the empty vector. 
Figure C shows the difference in growth between the non-induced and 
induced state of the lowest level-expressing clone as compared to the non-
induced and induced state of the empty vector. 
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3.6 Cell viability assay 
Approximately 4 x 104 cells of each ofpTRE2-Xrel3 (Int.) were 
seeded per well in a 6-wells plate. This was done for both the pTRE2-Xrel3 
(Int.) transfected cells and the control cells transfected with the empty 
vector. The cells were treated with 1 J.!M cisplatin for 6 days. On each day of 
the experiment, the cells were trypsinized and mixed gently with an equal 
volume of 4 % trypan blue. The cells were counted immediately using a 
hemocytometer. The viable cells appeared colorless or transparent. 
However, the dead cells were stained blue. Only the viable cells were 
counted. The average of 3 readings was taken per day. Results showed that a 
lower number of viable cells were observed with Xrel3 induction compared 
to the non-induced and control cells (Figure 3.8). A consistant significant 
difference was observed between the number of viable cells+/- doxycycline 
in all of the 6 repeats of the experiment. 
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Figure 3.8: Growth assay pTRE2-Xrel3 (Int.) +/- doxycycline after 
treatment with 1 p.tM cisplatin. The graph represents the difference 
between the number of cells +/- induction and the decreasing number of 
viable cells after treatment with 1 flM cisplatin versus the number of days 
during which the experiment was carried. Less viable cells were observed 
when induction is coupled with 1 flM cisplatin treatment compared to the 
pTRE2 control HeLa cells. The number of viable cells, after drug treatment, 
were counted using trypan blue exclusion assay. An equal volume of the cell 
suspension and 4% trypan blue were mixed by pipetting and the unstained 
viable cells only were counted by microscopy. The vertical axis represents 
X-Y, where X is the number of cells observed+/- doxycycline, and Y is the 
number of cells observed+/- doxycycline and 1 flM cisplatin. The horizontal 
axis represents the number of days. 
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3.7 Effect of doxycycline induction ofpTRE2-Xrel3 (INT.) on protein 
expression 
The expression of a variety of pro- and anti-apoptotic factors was 
determined using Western Blotting analysis. For these experiments, the 
pTRE2-Xrel3 (Int.) cells were used. 
A. Pro-apoptotic factors (Table 5): 
1. p53 
a) In the absence of cisplatin treatment, the tumor 
suppressor protein p53 showed an increase of up to 4 
fold when compared to the non-induced state (Figure 
3.9). 
b) At 1 J.1M cisplatin treatment, the tumor suppressor 
protein p53 showed a decrease of up to 3 fold (Figures 
3.9 and 3.10). 
c) At 5 J.1M cisplatin treatment, the tumor suppressor 
protein p53 showed a significant decrease ofP<O.OS 
relative to the control cells transfected with the empty 
vector (Figure 3.10). 
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d) After 48 hours of 1 ~ and 5 ~ cisplatin treatment, 
no significant difference was seen in the level of the 
tumor suppressor protein p53, +/-doxycycline (Figure 
3.11 ). This was the only experiment done after 48 hours 
of drug treatment in order to examine the effect of 
prolonged drug treatment on the cells. 
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Figure 3.9: Expression of p53 in pTRE2-Xrel3 (Int.) and control pTRE2 
transfected HeLa cells. The upper panel shows a Western blot analysis of 
the proteins extracted after 24 hours of 1 ~ cisplatin treatment from 
pTRE2-Xrel3 (Int.) cells and from pTRE2 control cells+/- doxycycline. The 
blot was probed with the mouse monoclonal IgG anti-p53 antibody and 
reprobed with ~-actin to serve as a control for equal protein loading. The 
lower panel shows the corresponding densitometry analysis of the results. 
The values represent the mean ± the standard deviation of 7 independent 
experiments. Protein expression was quantified by measuring the optical 
density of the bands at medium exposure of the X-ray film and then dividing 
the values by the corresponding ~-actin values. 
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Figure 3.10: Expression of p53 in pTRE2-Xrel3 (Int.) clone after 24 
hours of 1 and 5 J..LM cisplatin treatment. The upper panel shows the 
Western blot analysis of the proteins extracted after 24 hours of treatment 
with 1 and 5 J..LM cisplatin from pTRE2-Xrel3 (Int.) cells+/- doxycycline. 
The blot was probed with the mouse monoclonal lgG anti-p53 antibody and 
reprobed with ~-actin to serve as a control for equal protein loading. Protein 
expression was quantified by measuring the optical density of the bands at 
medium exposure of the X-ray film and then dividing the values by the 
corresponding ~-actin values. The lower panel shows the corresponding 
densitometry analysis of the results. The values represent the mean ± 
standard deviation of 3 independent experiments.**P<O.O 1 is the statisitical 
significance of the difference in p53 expression between pTRE2-Xrel3 (Int.) 
clone treated with 5 J..LM cisplatin and the corresponding non-induced clone. 
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Figure 3.11: Expression of p53 in the intermediate Xre13-expressing 
clones after 48 hours of drug treatment. The upper panel shows the 
Western blot analysis of the proteins extracted after 48 hours of treatment 
with 1 and 5 JlM cisplatin from pTRE2-Xrel3 (Int.) cells+/- doxycycline. 
The blot was probed with the mouse monoclonal IgG anti-p53 antibody and 
reprobed with B-actin to serve as a control for equal protein loading. Protein 
expression was quantified by measuring the optical density of the bands at 
medium exposure of the X-ray film and then dividing the values by the 
corresponding B-actin values. The lower panel shows the corresponding 
densitometry analysis of the results. 
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2. Bax 
a) At 1 j.!M cisplatin treatment, a significant decrease of 
the apoptotic protein Bax ofP<0.05 was observed 
relative to the non-induced state (Figure 3.12). 
b) At 5 j.!M cisplatin treatment, a significant increase of 
the apoptotic protein Bax ofP<0.05 relative to the 
control cells transfected with just the empty vector was 
observed (Figure 3.12). 
3. Caspase-3 
a) At 1 j.!M cisplatin treatment, the 17-kDa catalytic subunit 
of the apoptotic factor caspase-3 showed a decrease of 
0.3 fold relative to the non-induced state (Figure 3.13). 
b) At 5 j.!M cisplatin treatment, the 17- kDa catalytic subunit 
of the apoptotic factor caspase-3 showed a significant 
increase of P<0.05 relative to the 1 jlM cisplatin 
treatment (Figure 3.13). 
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Figure 3.12: Expression of Bax in pTRE2-Xrel3 (Int.) and pTRE2 
transfected HeLa cells after 24 hours of 1 and 5 !lM cisplatin treatment. 
The upper panel shows the Western blot analysis of the proteins extracted 
after 24 hours of treatment with 1 and 5 J..LM cisplatin from pTRE2-Xrel3 
(Int.) cells+/- doxycycline. Protein expression was quantified by measuring 
the optical density of the bands at medium exposure of the X-ray film and 
then dividing the values by the corresponding ~-actin values. The lower 
panel shows the corresponding densitometry analysis of the results. The 
values represent the mean± standard deviation. *P<0.05 is the statistical 
significance of the difference in Bax expression with Xrel3 induction 
relative to the non-induced state at 1 J..LM cisplatin, +P<0.05 is the statistical 
significance of the difference in Bax expression with Xrel3 induction 
relative to control at 5 J..LM cisplatin and **P<0.01 is the statistical 
significance of the difference in Bax expression in control cells with 
doxycycline as compared to without doxycycline at 5 J..LM cisplatin. 
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Figure 3.13: Expression of caspase-3 catalytic subunit at 17 kDa in 
pTRE2-Xrel3 (Int.) and pTRE2 transfected HeLa cells+/- doxycycline 
after 24 hours treatment with 1 and 5 IJM cisplatin. The upper panel 
shows the Western blot analysis of the proteins extracted after 24 hours of 
treatment with 1 and 5-J..LM cisplatin from pTRE2-Xrel3 (Int.) cells 
compared to the control cells+/- doxycycline. Protein expression was 
quantified by measuring the optical density of the bands at medium exposure 
of the X-ray film and then dividing the values by the corresponding ~-actin 
values. The lower panel shows the corresponding densitometry analysis of 
the results. The values represent the mean± standard deviation. **P<0.01 is 
the statistical significance of the difference in caspase-3 expression with 
Xrel3 induction relative to the non-induced state at 5 J..LM cisplatin and 
*P<0.01 is the statistical significance of the difference in caspase-3 
expression in control cells with doxycycline as compared to without 
doxycycline at 1 and 5-J..LM cisplatin. 
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4. Caspase-8 
a) In the absence of drug treatment, the 55-kDa catalytic 
subunit of the apoptotic factor caspase-8 showed an 
increase of up to 6 fold relative to the non-induced state 
(Figure 3.14). 
b) At 1 j..tM cisplatin treatment, the 55-kDa catalytic subunit 
of the apoptotic factor caspase-8 showed a significant 
decrease ofP<0.05 relative to control (Figures 3.14 and 
3.15). 
c) At 5 j..tM cisplatin treatment, the 55-kDa catalytic subunit 
of the apoptotic factor caspase-8 showed a significant 
increase ofP<0.05 relative to the 1 j..tM cisplatin 
treatment (Figure 3.15). 
S.MDM-2 
a) At 1 j..tM cisplatin treatment, MDM-2 showed a 
significant decrease ofP<0.01 relative to both the non-
induced state and to the control (Figure 3.16). 
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b) At 5 ~ cisplatin treatment, MDM-2 showed a 
significant increase ofP<0.05 relative to the non-induced 
state (Figure 3 .16). 
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Figure 3.14: Expression of caspase-8 at 55 kDa cleaved product in 
pTRE2-Xre13 (Int.) and pTRE2 transfected BeLa cells+/- doxycycline 
and +/- with 1 IJM cisplatin. The upper panel shows the Western blot 
analysis of the proteins extracted after 24 hours of treatment with 1 J..LM 
cisplatin from pTRE-Xrel3 (Int.) cells in comparison with the pTRE2 control 
clone+/- doxycycline. Protein expression was quantified by measuring the 
optical density of the bands at medium exposure of the X-ray film and then 
dividing the values by the corresponding ~-actin values. The lower panel 
shows the corresponding densitometry analysis of the results. The values 
represent the mean± standard deviation. +P<O.OS is the statistical 
significance of the difference in caspase-8 expression with Xrel3 induction 
relative to the control cells transfected with the empty vector at 1 J..LM 
cisplatin. 
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Figure 3.15: Expression of caspase-8 at 55 kDa cleaved product in 
pTRE2-Xre13 (Int.) and pTRE2 control clone +/- doxycycline after 24 
hours treatment with 1 and 5 IJM cisplatin. The upper panel shows the 
Western blot analysis of the proteins extracted after 24 hours of treatment 
with 1 and 5 J..LM cisplatin from pTRE2-Xrel3 (Int.) cells compared with the 
pTRE2 control cells+/- doxycycline. The blot was probed with the mouse 
monoclonal IgG anti-caspase-8 antibody and reprobed with ~-actin to serve 
as a control for equal protein loading. 
Protein expression was quantified by measuring the optical density of the 
bands at medium exposure of the X-ray film and then dividing the values by 
the corresponding ~-actin values. 
The lower panel shows the corresponding densitometry analysis of the 
results. The values represent the mean ± standard deviation of 3 independent 
experiments. +P<0.05 is the statistical significance of the difference in 
caspase-8 expression with Xrel3 induction relative to the control at 1 J..LM 
cisplatin, **P<0.05 is the statistical significance of the difference in caspase-
8 expression with induction and 5 J..LM cisplatin relative to the 1 J..LM cisplatin 
treatment, *P<0.05 is the statistical significance of the difference in caspase-
8 expression with doxycycline as compared to without doxycycline. 
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Figure 3.16: Expression of MDM-2 in pTRE2-Xrel3 (Int.) compared to 
the pTRE2 control +/- doxycycline and after 24 hours treatment with 1 
and 5 IJM cisplatin. The upper panel shows the Western blot analysis of the 
proteins extracted after 24 hours of treatment with 1 and 5 J.!M cisplatin from 
pTRE2-Xrel3 (Int.) in comparison with the pTRE2 control cells+/-
doxycycline. The blot was probed with the mouse monoclonal IgG anti-
MDM-2 antibody and reprobed with B-actin to serve as a control for equal 
protein loading. 
Protein expression was quantified by measuring the optical density of the 
bands at medium exposure of the X-ray film and then dividing the values by 
the corresponding B-actin values. 
The lower panel shows the corresponding densitometry analysis of the 
results. The values represent the mean ± standard deviation of 3 independent 
experiments. **P<0.01 is the statistical significance ofthe difference in 
MDM-2 expression at 1 J.!M cisplatin with Xrel3 induction relative to the 
non-induced and to the control state as well and *P<0.05 is the statistical 
significance of the difference in MDM-2 expression with Xrel3 induction at 
5 J.!M cisplatin relative to the non-induced state. 
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6. Bcl-2 
a) At 1 ~ cisplatin treatment, a significant decrease in 
Bcl-2 ofP<0.01 relative to the control cells transfected 
with the empty vector and relative to the non-induced state 
was observed (Figure 3.17). 
b) At 5 J..LM cisplatin treatment, a significant increase in 
Bcl-2 ofP<0.01 relative to the control cells transfected 
with just the empty vector and relative to the non-induced 
state was observed (Figure 3.17). 
7. Bci-XL 
a) At 1 J..LM cisplatin treatment, a significant decrease of P< 
0.01 relative to the control cells transfected with just the 
empty vector and P<0.05 relative to the non-induced state 
was observed (Figure 3.18). 
b) At 5 J..LM cisplatin treatment, a significant increase of 
P<0.01 relative to the control cells transfected with the 
empty vector and P<0.05 relative to the non-induced state 
was observed (Figure 3.18). 
103 
Figure 3.17: Expression ofBcl-2 in pTRE2-Xrel3 (Int.) compared to the 
pTRE2 control +/- doxycycline and after 24 hours treatment with 1 and 
5 IJM cisplatin. The upper panel shows a Western blot analysis of the 
proteins extracted after 24 hours of treatment with 1 and 5 1-1M cisplatin from 
pTRE2-Xrel3 (Int.) cells in comparison with the pTRE2 control cells+/-
doxycycline. The blot was probed with the mouse monoclonal IgG anti-Bcl-
2 antibody and reprobed with ~-actin to serve as a control for equal protein 
loading. Protein expression was quantified by measuring the optical density 
of the bands at medium exposure of the X-ray film and then dividing the 
values by the corresponding ~-actin values. The lower panel shows the 
corresponding densitometry analysis of the results. The values represent the 
mean± standard deviation of3 independent experiments.** P<0.005 is the 
statistical significance of the difference in Bcl-2 expression with Xrel3 
induction relative to both control and non-induced cells. 
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Figure 3.18: Expression of Bcl-XL in pTRE2-Xrel3 (Int.) compared to 
the pTRE2 control +/- doxycycline and after 24 hours treatment with 1 
and 5 IJM cisplatin. The upper panel shows the Western blot analysis of the 
proteins extracted after 24 hours of treatment with 1 and 5 J.!M cisplatin from 
pTRE2-Xrel3 (Int.) cells in comparison with the pTRE2 control cells+/-
doxycycline. The blot was probed with the mouse monoclonal IgG anti-Bcl-
XL antibody and reprobed with ~-actin to serve as a control for equal protein 
loading. 
Protein expression was quantified by measuring the optical density of the 
bands at medium exposure of the X-ray film and then dividing the values by 
the corresponding ~-actin values. 
The lower panel shows the corresponding densitometry analysis of the 
results. The values represent the mean± standard deviation.** P<0.01 is the 
statistical significance of the difference in Bel-XL expression with Xrel3 
induction relative to the non-induced state at 1 and 5 IJM cisplatin. 
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8. PARP 
a) In the absence of drug treatment, the 85-kDa catalytic 
subunit of the apoptotic factor P ARP showed a 
significant increase ofP<0.01 relative to the non-induced 
state and relative to the control (Figure 3.19). 
b) At 1 ~ cisplatin treatment, the 85-kDa catalytic subunit 
of the apoptotic factor PARP showed a 2-fold increase 
relative to the non-induced state (Figure 3 .20). 
c) At 5 ~ cisplatin treatment, the 85-kDa catalytic subunit 
of the apoptotic factor P ARP showed a 3.1 fold increase 
relative to the non-induced state (Figure 3 .20). 
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Figure 3.19: Expression of P ARP in pTRE2-Xrel3 (Int.) cells compared 
to the pTRE2 control cells +/- doxycycline. The upper panel shows the 
Western blot analysis of the proteins extracted after 24 hours from pTRE2-
Xrel3 (Int.) cells in comparison with the pTRE2 control cells+/-
doxycycline. The blot was probed with the mouse monoclonal IgG anti-
human P ARP antibody and repro bed with ~-actin to serve as a control for 
equal protein loading. Protein expression was quantified by measuring the 
optical density of the bands at medium exposure of the X-ray film and then 
dividing the values by the corresponding ~-actin values. The lower panel 
shows the corresponding densitometry analysis of the results. The values 
represent the mean ± standard deviation of 3 independent experiments. 
** P<O.OOS is the statistical significance of the difference in PARP 
expression of the 85 kDa catalytic subunit indicating apoptosis with Xrel3 
induction without treatment relative to both control and non-induced cells. 
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Figure 3.20: Expression of P ARP 85 kDa catalytic subunit in pTRE2-
Xrel3 (Int.) compared to the pTRE2 control+/- doxycycline and after 24 
hours treatment with 1 and 5 IJM cisplatin. The upper panel shows the 
Western blot analysis of the proteins extracted after 24 hours of treatment 
with 1 and 5 J.LM cisplatin from pTRE2-Xrel3 (Int.) cells in comparison with 
the pTRE2 control cells +/- doxycycline. The blot was probed with the 
mouse monoclonal IgG anti-human P ARP antibody and repro bed with ~­
actin to serve as a control for equal protein loading. 
Protein expression was quantified by measuring the optical density of the 
bands at medium exposure of the X-ray film and then dividing the values by 
the corresponding ~-actin values. 
The lower panel shows the corresponding densitometry analysis of the 
results. The values represent the mean ± standard deviation of 5 independent 
experiments. 
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B. Cell Cycle Regulators 
1. p21 
a) In the absence of drug treatment a significant increase 
in p21 was observed relative to the non-induced and 
control cells (Figure 3.21 A). 
b) At 1 ~M cisplatin treatment, a decrease in p21 of up to 
0.4 fold was observed relative to the non-induced state 
(Figure 3.21 B). 
c) At 5 ~M cisplatin treatment, a significant increase in 
the cell cycle regulator p21 ofP<0.01 relative to the 
control cells transfected with the empty vector was 
observed (Figure 3.21 B). 
2. Cyclin Dl 
a) At 1 ~M cisplatin treatment, an increase in cyclin D1 of 
0.4 fold relative to the control was observed (Figure 
3.22). 
b) At 5 ~M cisplatin treatment, an increase in the cyclin 
D1 of0.2 fold relative to the non-induced state was 
observed (Figure 3.22). 
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3. PCNA 
a) At 1 ~ cisplatin treatment, the proliferating cell 
nuclear antigen (PCNA) showed a significant decrease 
ofP<O.Ol relative to the control cells transfected with 
the empty vector and P<O.OS relative to the non-
induced state (Figure 3.23). 
b) At 5 J.LM cisplatin treatment, PCNA showed a 
significant increase ofP<O.Ol relative to the non-
induced state and the control (Figure 3.23). 
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Figure 3.21: Expression of p21 in pTRE2-Xre13 (Int.) compared to the 
pTRE2 control +/- doxycycline and after 24 hours treatment with 1 and 
5 IJM cisplatin. Figure (A) shows the Western blot analysis of the proteins 
extracted from the pTRE2-Xrel3 (Int.) cells+/- doxycycline and without 
drug treatment. Figure (B) shows the Western blot analysis ofpTRE2-Xrel3 
(Int.) cells in comparison with the pTRE2 control clone+/- doxycycline and 
+/-with 1 and 5 ~M cisplatin. Protein expression was quantified by 
measuring the optical density of the bands at medium exposure of the X-ray 
film and then dividing the values by the corresponding ~-actin values. 
Figure (C) shows the corresponding densitometry analysis of the results. 
The values represent the mean ± standard deviation of 4 independent 
experiments. **P<O.Ol is the statistical significance of the difference in p21 
expression with Xrel3 induction at 5 11M cisplatin relative the control. 
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Figure 3.22: Expression of cyclin Dl in pTRE2-Xrel3 (Int.) compared to 
the pTRE2 control +/- doxycycline and after 24 hours treatment with 1 
and 51JM cisplatin. The upper panel shows the Western blot analysis ofthe 
proteins extracted after 24 hours of treatment with 1 and 5 J..LM cisplatin from 
pTRE2-Xrel3 (Int.) cells in comparison with the pTRE2 control cells+/-
doxycycline. Protein expression was quantified by measuring the optical 
density of the bands at medium exposure of the X-ray film and then dividing 
the values by the corresponding ~-actin values. 
The lower panel shows the corresponding densitometry analysis of the 
results. The values represent the mean ± standard deviation of 3 independent 
experiments. 
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Figure 3.23: Expression of PCNA in pTRE2-Xrel3 (Int.) compared to 
the pTRE2 control +/- doxycycline and after 24 hours treatment with 1 
and 5 IJM cisplatin. The upper panel shows the Western blot analysis of the 
proteins extracted from pTRE2-Xrel3 (Int.) cells in comparison with the 
pTRE2 control cells+/- doxycycline. Protein expression was quantified by 
measuring the optical density of the bands at medium exposure of the X-ray 
film and then dividing the values by the corresponding ~-actin values. 
The lower panel shows the corresponding densitometry analysis of the 
results. The values represent the mean ± standard deviation of 3 independent 
experiments. **P<O.Ol is the statistical significance of the difference in 
PCNA expression with Xrel3 induction at 1 and 5 J.LM cisplatin relative to 
both the non-induced and the control. 
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C. Anti-apoptotic factors 
BAG-1 
a) At 1 j.!M cisplatin treatment, the p29 isoform ofBAG-1 
showed a significant increase ofP<0.05 relative to the 
non-induced state and the control cells (Figure 3.25). 
Also the p33, p46 and p50 isoforms ofBAG-1 showed 
a significant increase ofP<0.01 relative to both the 
non-induced and control cells (Figure 3.24). 
b) At 5 j.!M cisplatin treatment, the p29 isoform ofBAG-1 
showed a significant decrease ofP<0.01 relative to the 
non-induced state (Figure 3.25). Also, the p33, p46 and 
p50 isoforms ofBAG-1 showed an increase ofP<0.01 
relative to the non-induced state (Figure 3.24). 
D. HPV 16/18 E6 
No significant changes were observed in the 2 subunits at 1 j.!M 
cisplatin treatment+/- doxycycline (Figure 3.26). 
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Figure 3.24: Expression ofBAG-1 p46 isoform in pTRE2-Xrel3 (Int.) 
compared to the pTRE2 control +/- doxycycline and after 24 hours 
treatment with 1 and 5 IJM cisplatin. The upper panel shows Western blot 
analysis of the proteins extracted after 24 hours of treatment with 1 and 5 
f..LM cisplatin from pTRE2-Xrel3 (Int.) cells in comparison with the pTRE2 
control cells+/- doxycycline. The lower panel shows the corresponding 
densitometry analysis of the results. The values represent the mean ± 
standard deviation of 5 independent experiments. 
** P<0.01 is the statistical significance ofthe difference in BAG-1 p46 
isoform expression with Xrel3 induction relative to the non-induced state, 
++P<0.01 is the statistical significance ofthe difference in BAG-1 p46 
isoform expression with Xrel3 induction relative to the control. 
Similar results were obtained for p33 and p50 isoforms ofBAG-1. 
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Figure 3.25: Expression ofBAG-1 p29 isoform in pTRE2-Xrel3 (Int.) 
cells compared to the pTRE2 control cells +/- doxycycline and after 24 
hours treatment with 1 and 5 IJM cisplatin. The result shows the 
corresponding densitometry analysis of the results. The values represent the 
mean ± standard deviation of 5 independent experiments. 
** P<O.Ol is the statistical significance ofthe difference in BAG-1 p29 
isoform expression with Xrel3 induction relative to the non-induced state, 
*P<O.Ol is the statistical significance ofthe difference in BAG-1 p29 
isoform expression with Xrel3 induction relative to the non-induced state. 
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Figure 3.26: Expression of HPV 16/18 E6 in pTRE2-Xrel3 intermediate 
level-expressing clone compared to the pTRE2 control +/- doxycycline 
and after 24 hours treatment with 1 and 5 IJM cisplatin. The upper panel 
shows a Western blot analysis of the proteins extracted after 24 hours of 
treatment with 1 and 5 J.LM cisplatin from pTRE2-Xrel3 (Int.) cells in 
comparison with the pTRE2 control cells+/- doxycycline and+/- with 1 and 
5 IJM cisplatin. Protein expression was quantified by measuring the optical 
density of the bands at medium exposure of the X-ray film and then dividing 
the values by the corresponding ~-actin values. 
The lower panel shows the corresponding densitometry analysis of the 
results. 
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Summary: Effect of Xrel3 expression on BeLa cellular 
protein extracts 
l.n..pup~..otic facto~ ..... ""nt 1 J..lM cisplatin 5 J..lM cisplatin 
iP53 Increase up to 4 fold Decrease up to 3 Significant 
compared to the non- fold relative to the decrease P<0.05 
induced state non-induced state. relative to control. 
Bax !Decrease P<O .05 Increase P<0.05 
1relative to non- relative to control. 
!induced state. 
---- --·-··-
Bcl-2 !Decrease P<0.01 Increase P<O.O 1 
!relative to control relative to control 
and non-induced and non-induced 
state. state. 
BCL-XL Decrease P<O. 0 1 Increase P<0.01 
relative to control relative to control 
andP<0.05 and P<0.05 
relative to non- relative to non-
induced state. induced state. 
Caspase-3 iDecrease 0.3 fold 1Increase P<0.05 
!relative to the non- !relative to 1 J..lM 
!induced state. cisplatin. 
PARP !Increase P<0.01 !Increase up to 2 Increase up to 3 .1 
!relative to non-induced fold relative to the fold relative to the 
state and relative to the non-induced state. non-induced state. 
control 
Caspase-8 Increase up to 6 fold 1Decrease relative Increase P<0.05 
,relative to non-induced ito control P<0.05 relative to 1 J..lM 
is tate cisplatin. 
IMDM-2 Decrease P<O. 01 Increase P<0.05 
relative to both the relative to the non-
non-induced state induced state. 
and to the control. 
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Cell cycle 
,regulators 
p21 [Increase relative to the Decrease up to 0.4 Increase P<O.O 1 
non-induced and fold relative to the relative to control. 
control cells. non-induced state. 
CyclinD1 Increase 0.4 fold Increase 0.2 fold 
from control. from non-induced 
state. 
PCNA Decrease P<O.O 1 Increase P<O.O 1 
relative to control relative to non-
andP<0.05 induced and the 
!relative to non- control. 
induced state. 
Anti -apoptotic 
factors 
iBAG-1 p29: Increase p29: Decrease 
P<0.05 relative to P<0.01 relative to 
both the non- the non-induced 
induced and state. 
control cells. 
p33, 46, 50: 
p33, 46, 50: Increase P<0.01 
Increase P<O.O 1 relative to non-
relative to both the induced state. 
non-induced and 
the control. 
Table 5: Modulation of the proteins by the effect of Xrel3 
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CHAPTER 4: DISCUSSION AND FUTURE DIRECTIONS 
In this thesis, I wanted to determine the effect of Xre/3 expression on 
HeLa cells in response to chemotherapeutic agents. Because of its homology 
to the mammalian Rel/NF-KB family and because of its effects in embryos, I 
speculated that Xre/3 could have a role in promoting tumor formation. Its 
ability to support the survival of HeLa cells in the presence of 1 ~ cisplatin 
indicated that it has a tumor-promoting activity by inhibiting apoptosis under 
mild-moderate stress conditions. 
The objectives of this study were: 
1. Generation of Xre/3 inducible system. This was accomplished by 
creating an inducible Tet-On system that was capable of inducing the 
expression of Xre/3 gene that is located downstream of the tet 
promoter. My results show a clear induction ofXrel3 from a baseline 
of no expression in at least 4 transfected pTRE2-Xrel3 clones (Figure 
3.6). This inducible system is a convenient way ofstudyingXre/3 
expression as it allows Xre/3 expression only upon the addition of 
doxycycline. 
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2. To examine the effect of Xrel3 expression on growth. The growth 
of He La cervical cells expressing Xrel3 was compared to similar cells 
not expressing Xrel3. The results of the growth assays were also 
compared to HeLa cells transfected with just the empty vector, which 
served as a control. In these experiments, I found that High and Low 
expressing clones did show a growth differential, but the Intermediate 
expressing clone showed the greatest growth inhibition in the 
presence ofXrel3. The reason behind these observations might be due 
to the slight differences in the genomic sequence encountered after the 
insertion of Xrel3 into the HeLa cellular genome. Slight changes even 
by 1 or 2 nucleotides might have a great impact on gene expression 
and activity (Gerondakis et al., 1999). 
3. To examine the effect of Xrel3 on the growth of cisplatin treated 
HeLa cells. I found that at 1 j.!M cisplatin, Xrel3 provided an anti-
apoptotic effect after 24 hours of treatment. This was based on the 
significantly lower levels of the apoptotic proteins, Bax (P<0.05), 
caspase-8 (P<0.05) and MDM-2 (P<0.01). Furthermore, the level of 
the tumor suppressor protein p53 was suppressed up to 3-fold, along 
with a reduction of caspase-3 and p21, as well. The anti-apoptotic 
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BAG-1 isoforms (P<0.01) were also upregulated. However, after 24 
hours of 5 ~M cisplatin treatment, a significant increase in the levels 
of the pro-apoptotic proteins was seen relative to controls. These 
included: Bax (P<O.OS), MDM-2 (P<O.OS), the cell cycle inhibitor p21 
(P<0.01), cleaved PARP, caspase-8, and caspase-3. However, p53 was 
significantly decreased (P<O.OS). BCL-2 (P<0.01) and BCL- XL 
(P<0.01) were elevated significantly. The anti-apoptotic protein BAG-
1 remained constant (P<O.O 1) in cisplatin-treated Xrel3-expressing 
cells. Despite the upregulation of BAG-1, the balance shifted towards 
apoptosis by the increased expression of the pro-apoptotic proteins. 
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4.1 Tet-On system and Xrel3 expression 
rtTA 
BD Tet-On 1M System 
A.rtTA( #> 
binds TRE and activates transcription 
In the presence of DOX 
Figure 4.1: The mechanism of action of the Tet-On system (adapted from 
BD Biosciences Clontech catalog, 2003). The reverse tetracycline-controlled 
trans-activator (rtTA) induces transcription of the gene of interest only in the 
presence of doxycycline (1 J.tg/ml). The rtTA is in turn composed of the 
activation domain, VP16, and the reverse tet-repressor protein, rtetR 
sequences. The rtT A then binds the tetracycline-responsive element (TRE) 
and activates transcription in the presence of doxycycline. 
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The double-stable transfection ofHeLa Tet-On cells with Xrel3 
showed positive transcription of Xre/3 as detected by Northern blotting. The 
rest of the clones were excluded because they expressed spurious sequences 
or exhibited leaky transcription, perhaps due to the integration of the 
trans gene in a location on the heterochromatin that is of a high 
transcriptional activity (Alarcon et al., 1999). 
4.2 Effect of Xre13 expression on growth 
The expression of Xrel3 in the double-stable HeLa cell line 
transfected with pTRE2-Xrel3 was found to be associated with a significant 
decline in the rate of growth of cells as seen in 6 independent experiments. 
This decline was seen in all of the three selected clones with different levels 
ofXrel3 expression, that is, the highest-level, intermediate-level and lowest-
level expressing clones. This decline was in comparison to the non-induced 
state when no doxycycline was added. As mentioned before, Xrel3 is a 
homolog of cRel, which is a member of the Rel/NF-KB family. However, 
NF-KB is not normally expressed in HeLa cells (Gerondakis et al., 1999). It 
is interesting, therefore, that the stable integration and expression of Xrel3 in 
135 
HeLa cells caused their rate of growth to slow down in comparison to 
control cells transfected with pTRE2 vector. The decline in growth in the 
Xrel3-expressing clone was significant starting on day 3 in all of the tested 
clones, initiated with 4 x 104 cells seeded/well in 6-wells plates. This means 
that a lag period of 3 days was a consistant observation in all of the 
examined clones. This might be attributed to the anti-apoptotic effects of the 
Rel/NF -KB family and its ability to promote cell survival under mild-
moderate stress conditions (See Introduction). 
The intermediate-level expressing clone exhibited the highest 
differences in cell growth with and without induction as compared to the 
highest and lowest-Xrel3 expressing clones. The decline in the growth rate 
of He La cells after Xrel3 expression might be attributed to the ability of NF-
KB to induce the expression of the cell cycle inhibitor p21 (Seitz et al., 2000; 
Seitz et al., 1998). My results showed a dramatic increase in p21 in the 
HeLa-transfected cells after induction of Xrel3 expression by doxycycline as 
compared to the decrease in p21 level in the untransfected cells induced by 
doxycycline. These observations were supported by previous findings. For 
example, the NF-KB subunits were found to arrest the growth of normal 
epithelial cells and this growth arrest was found to be coupled with high 
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p21 Cipt expression (Seitz et al., 2000; Seitz et al., 1998). The p21 protein is 
one of the cell cycle regulators known to block the G 1/S transition of the cell 
cycle and prevent aneuploidy by increasing the cell doubling time and G !-
arrested cell cycle (for review, see Rich et al., 2000; Chen et al., 1996). 
Interestingly, I also found that the cleaved P ARP dramatically 
increased in Xrel3-expressing HeLa cells as compared to the non-induced 
and control cells. This suggests that the cells are undergoing extensive DNA 
repair (for review, see Rich et al., 2000), thus cell exhaustion and decline in 
growth rate might be the possible consequences. 
Another possible explanation is that the cells might be on the first 
steps of undergoing apoptosis. My results showed an increase in the caspase-
8 catalytic subunit levels, which is used as an indicator of apoptosis, up to 6 
fold relative to the non-induced pTRE2-Xrel3 transfected HeLa cells (for 
review, see Rich et al., 2000). Caspase-8 is known to be a key molecule in 
the initiation of apoptosis (for review, see Krammer, 2000; Hengartner, 
2000). 
Furthermore, overexpression of c-Rel was found to be associated with 
apoptosis in bone marrow cells in vitro (Abbadie et al., 1993) and in stably 
transfected HeLa cells depending on the stimulus (Kaltschmidt et al., 2000). 
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Thus, the increased levels of p21 and consequent growth arrest followed by 
activation of caspase-8 might be the first steps in initiating apoptosis by 
Xrel3 overexpression. Further studies could be done to directly assay 
apoptosis using other cellular means such as TUNEL, TB exclusion and 
DNA fragmentation assays. 
4.3 Effect of Xrel3 expression on cisplatin-treated BeLa cells. 
Results of the cell viability assays showed lower numbers of cells 
surviving when Xrel3 was expressed in HeLa cells treated with 1 JlM 
cisplatin over a period of six days as compared to the non-induced HeLa 
cells and control cells. The decline in the number of cells started to be 
significant on the third day of 1 JlM cisplatin treatment. This might indicate 
that Xrel3 expression chemosensitizes the cells to cisplatin. However, this 
chemosensitization was not apparent on day 1 or day 2 of the experiment, 
but it started to appear on day 3 and continued till day 6 of the experiment. 
In previous studies, Rel/NF-KB was shown to provide a protective effect to 
the cells in response to stress (for review, see Chen et al., 1998; Verma et 
al., 1995). Rel/NF-KB is known to promote cell survival (Liou et Baltimore, 
1993; May and Ghosh, 1998). These cell-survival effects of Rel/NF -KB 
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might be the reason behind the lag period of 2 days before a prominent 
chemosensitization was clear in HeLa cells. 
With prolonged exposure to 1 ~ cisplatin, chemosensitization was 
observed. It is possible that prolonged cisplatin exposure might initiate other 
apoptotic mechanisms that override the protective effect of Xrel3. I tried to 
examine the effect of 5 J.!M cisplatin on cell viability, but the cells showed 
such a fast rate of killing in the first 3 days that I could not examine whether 
Xrel3-induced chemosensitization will start from day 1 when the cells were 
exposed to a more potent dose stimulus. 
NF-KB-induced chemosensitization is supported by previous research 
in the field. For example, NF-KB and AP-1 were found to stimulate the 
expression of the pro-apoptotic Fas ligand (Fas) protein and this was in 
direct response to chemotherapeutic drug treatment or T -cell activation 
signals (Baldwin, 2001; Barkett and Gilmore, 1999). Furthermore, NF-KB 
activation played a significant role in doxorubicin-induced apoptosis (Muller 
et al., 2003) and in paclitaxel-induced apoptosis (Huang et al., 2000). Still, 
in my experiments, the intermediate Xrel3-expressing clone showed the 
greatest variation on the growth curve +/- doxycycline after 1 J.!M cisplatin 
treatment, thus following a similar pattern to the growth curves without drug 
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treatment. These results and conclusions were based on 6 independent 
experiments, all of which showed the same pattern. 
4.4 Modulation of protein expression by Xrel3 overexpression. 
The overexpression of Xrel3 caused an anti-apoptotic effect on HeLa 
cells treated with 1 J!M cisplatin for 24 hours. However, when HeLa cells 
were treated with 5 J!M cisplatin for 24 hours, Xrel3 over expression caused 
an apoptotic effect synergistic to cisplatin when compared to the non-
induced Xrel3-transfected HeLa cells and the control cells transfected with 
the empty vector. 
Previous studies have shown that NF-KB might have an anti-apoptotic 
or a pro-apoptotic effect depending on the nature of the stimulus to which 
the cell is exposed (Kaltschmidt, 2000). The levels of the different proteins 
examined gave some insight on the possible mechanism of action of c-Rel 
overexpression in cisplatin-treated HeLa cells. When no drug was added, 
Xrel3 provided a cell survival and a protective effect to HeLa cells and this 
effect was demonstrated by slowing the growth of the cells as illustrated in 
the growth assays and the induction of p21, which promotes cell cycle arrest. 
Therefore, the cells may be protected from undergoing apoptosis by the 
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replicating cells that acquire more damage to their replicating DNA. Also 
Xrel3 provided an initial anti-apoptotic effect when the cells were treated 
with 1 pM cisplatin as measured by the expression of pro- and anti-apoptotic 
markers; however, with prolonged exposure to the 1 pM cisplatin or with 5 
~ cisplatin, Xrel3 exhibited an apoptotic effect synergistic with the 
cisplatin and therefore caused chemosensitization of HeLa cells. 
4.4.1 Xrel3 effect on protein expression at 1 JIM cisplatin-treated BeLa 
cells. 
The modulation of the different proteins expressed after 24 hours of 1 
pM cisplatin-treated cells by the effect of Xrel3 suggests a mechanism of 
action of Xrel3. This was shown by the significant upregulation of anti-
apoptotic factors and downregulation of apoptotic factors as follows: 
1. A significant decrease in the apoptotic protein Bax (P<0.05) relative 
to the non-induced state. 
2. A significant decrease in caspase-8 protein catalytic subunit (55-kDa) 
of the pro-apoptosis cascade (P<0.05) relative to the control cells was 
seen. The catalytic subunit is an indicator of active apoptosis. 
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3. Caspase-3 levels of the cleaved product at 17-kDa were decreased 0.3 
fold relative to the non-induced state. 
4. The tumor suppressor protein p53, showed a decrease of up to 3 fold 
indicating that NF-KB is potentiating the anti-apoptotic effect and 
promoting cell survival. 
5. MDM-2, which is a p53-induced protein was significantly decreased 
(P<0.01) as is expected. 
6. The BAG-1 anti-apoptotic isoforms p33, p46, p50 were found to be 
significantly increased presumably to promote survival and inhibit 
apoptosis. 
7. Interestingly, p21 levels were decreased when HeLa cells were 
exposed to 1 ~ cisplatin treatment, indicating that Xrel3 was 
working hard to prevent apoptosis and promote cell cycle progression 
and cell survival in response to the stimulus threatening the cells. But 
when no drug treatment was applied, NF -KB caused an induction of 
p21 levels in an attempt to arrest further cell growth and protect the 
cells from overproliferation. Thus, a decline in the growth rate was 
observed on day 3 of the experiment 
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8. The poly(ADP-ribose) polymerase , PARP, was increased up to 2 
fold, perhaps cooperating with other factors in repairing the damage 
that is happening to the DNA by the effect of the 1 ~ cisplatin 
treatment. 
9. Cyclin D 1, which is a cell cycle regulator showed a slight increase 
indicating that the cells are undergoing proliferation and mitosis. 
Cyclin D1 is known to be significantly upregulated in cancers (Yu et 
al., 2001). However, recent studies have associated cell cycle arrest 
with high levels of cyclin D 1 (Pratt and Niu, 2003 ). 
10. The proliferating cell nuclear antigen (PCNA) levels were 
significantly decreased (P<0.01) relative to control and (P<0.05) 
relative to the non-induced state. This protein is responsible for 
proliferation and is usually upregulated in cancers. However, 
statistical studies have found that a high PCNA score has no 
significance in predicting chemosensitization or cell survival (Botti et 
al., 1993). 
11. The E6 oncoprotein expressed by HPV -16118 showed no significant 
changes in both the Xrel3-expressing clone and the control. 
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Thus, at moderate stress levels, the molecular response of cells that 
express Xrel3 suggests a possible anti-apoptotic and cell survival effect. 
This was reinforced by the upregulation of the anti-apoptotic markers 
(BAG-1) and the downregulation of the pro-apoptotic markers (Caspase-
3, Caspase-8, Bax, Bcl-2, p53, Mdm-2). 
4.4.2 Xrel3 effect on protein expression at 5 JIM cisplatin-treated HeLa 
cells. 
The overexpression of Xrel3 demonstrated a synergistic apoptotic 
effect to the cisplatin when HeLa cells were treated with 5 ~ cisplatin for 
24 hours as assayed by marker expression analyses. The chemosensitization 
of HeLa cells to cisplatin after Xrel3 expression was clearly supported by 
the significant upregulation of the apoptotic proteins: caspase-3, caspase-8, 
Bax and MDM-2. Also p21, which is a cell cycle inhibitor, was upregulated 
significantly relative to the control cells transfected with the empty vector. 
The cleaved P ARP level was increased up to 3.1 folds compared to the non-
induced state. Interestingly, we found that p53 levels remained low and after 
5 ~ cisplatin treatment, the decrease in p53 levels became significant 
compared to the control cells transfected with just the empty vector. Recent 
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studies showed that tumor cells expressing high levels of p53 showed poor 
response to cisplatin treatment and consequent resistance (Nakayama et al., 
2003). Thus, the low levels ofp53 caused by Xrel3 overexpression might be 
the reason behind the Xrel3-induced chemosensitivity. Another possible 
explanation of the chemosensitization is the ubiquitin-mediated degradation 
of p53 by the HPV18 E6 protein when HeLa cells were exposed to a more 
potent stimulus (5 ~ cisplatin) (Cohen et al., 2003). This idea is supported 
by the significantly high levels of MDM-2, which might have been induced 
by p53. 
Another possible reason behind the low p53 levels is the high level of 
Bcl-2. Recent data showed that overexpression of Bcl-2 suppresses p53 
expression (Jiang and Milner, 2003). My results showed that the anti-
apoptosis BAG-I p33, p46 and p50 protein isoforms levels remained 
significantly high after 5 ~ cisplatin treatment. In contrast, there was a 
significant increase in the levels of Bcl-2 and Bcl-XL relative to both the 
non-induced and control cells. Bcl-2 and Bcl-XL are known anti-apoptotic 
factors, which promote cell survival and protect the cells from apoptosis 
(Shinoura et al., 2000). However, recent research data provided evidence of 
the ability of Bcl-2 and Bel-XL to delay the cell cycle progression induced 
145 
by myc (Greider et al., 2002). As previously mentioned, one of the 
mechanisms of action of NF-KB, as an anti-apoptotic protein, is the 
upregulation of myc (for review, see Foo and Nolan, 1999; Chen et al., 
1998). Strikingly, I found that Bcl-2 and Bcl-XL levels increased 
significantly after 5 J,lM cisplatin treatment, when the cells are purportedly 
undergoing apoptosis. Therefore, overexpression of Bcl-2 and Bcl-XL might 
contribute to the p53 suppression-mediated cell growth arrest and the 
synergistic apoptotic effect induced by Xrel3. Previous studies have shown 
that induction of Bcl-2 in glioblastoma cells promoted apoptosis (Shinoura 
et al., 2000). 
In conclusion, my results indicate that high concentrations of cisplatin 
cause significant upregulation of the apoptotic factors Bax, MDM-2, 
caspase-3 and caspase-8. Despite the upregulation of the anti-apoptotic 
factor BAG-1 isoforms by cisplatin and Xrel3 expression, the balance 
shifted towards apoptosis and a synergistic effect was achieved in promoting 
cell death by NF-KB when coupled with cisplatin. The study of the 
modulation of the different proteins expressed in response to Xrel3 
expression provides new insights into the possible mechanism of action of 
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Rel/NF -KB in cell survival and apoptosis in response to chemotherapeutic 
drugs. 
4.5 Future Directions 
The HeLa-Tet On double transfected stable cell lines provide a 
powerful way of examining the effect of expression of any gene of interest 
inserted into the genome of HeLa cells. The expression of the gene of 
interest is simply turned on by the addition of doxycycline. However, no 
expression is detected in the absence of doxycycline. After examining the 
modulation of proteins caused by Xrel3 induction, more experiments are 
required to confirm and support the results obtained. 
The following experiments can be done: 
1. Detection of Fas, which 1s a marker of apoptosis 
mediated by the TNF receptor family. IfFas is detected when Xrel3 is 
expressed in the HeLa cells, it will support our results of the ability of 
Xrel3 to induce apoptosis. 
2. Gene microarray technology is a highly sophisticated 
method in determining which genes, other than the ones I examined, 
might be turned on when Xrel3 is overexpressed. The knowledge of 
the concomittant expression of different genes might give a clear 
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representation of the pathways involved in cell survival and apoptosis 
induced by Xrel3. It will also allow understanding of the factors that 
shift the function of Xre/3 from cell protection and promotion of 
survival to one of inducing cell death and apoptosis. This might be 
essential in targeting NF-KB for clinical therapeutic purposes. 
3. The possible utilization of a different control than the 
empty vector. For example, a control that inhibits NF-KB translocation 
to the nucleus like IKB, might serve as a good control. Therefore, 
HeLa cells will be transfected with the same pTRE2-Xrel3 plasmid, 
but the control cells will be transfected with or without the pTRE2-
Xrel3 plasmid with IKB in order to prevent the activation ofNF-KB. In 
this case, the effects of induction and inhibition of NF -KB can be 
examined. 
4. Examine the dose-response curve usmg vanous 
concentrations of cisplatin on different cell lines when NF -KB is 
activated and then determining the concentration associated with the 
shortest time required to achieve effective killing. Achieving tumor 
cell specificity is important for therapeutic purpose. 
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5. Examine other chemotherapeutic drugs belonging to 
different classes, for example: alkylating agents, nitrogen mustards, 
plant alkaloids and the miscellaneous group. These experiments will 
determine whether the other drugs affect the growth, apoptosis and 
expression of apoptosis regulating proteins of HeLa cells expressing 
or not expressing Xrel3 similarly to cisplatin or they show different 
responses depending on the group from which they are derived. 
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APPENDIX! 
t = ~=(difference between means)/(weighted average of 
vs 2 (;+~) 
standard deviations) 
2 (n -1 }y x 2 + (m - 1 }y / s =----------~-
n+m-2 
x = the average for the first sample 
y = the average for the second sample 
n = number of data points in the first sample 
m = number of data points in the second sample 
Sx = standard deviation of first sample (in formula #2 above, square 
the standard deviation = s/) 
Sy = standard deviation of second sample (in formula #2 above, square 
the standard deviation = sy 2) 
Degrees of Freedom: d.f. = n + m- 2 
Table 4: Computation of the Student's t-test. 
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